BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1424] [Cited by in F6Publishing: 1275] [Article Influence: 284.8] [Reference Citation Analysis]
Number Citing Articles
1 Goni E, Tammer I, Schütte K, Thon C, Jechorek D, Mahajan UM, Vasapolli R, Macke L, Aulinger B, Selgrad M, Link A, Malfertheiner P, Schulz C. The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients. Front Microbiol 2022;13:938676. [DOI: 10.3389/fmicb.2022.938676] [Reference Citation Analysis]
2 Chen YC, Li YD, Yu BH, Chen YC. A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease. BMC Gastroenterol 2022;22:416. [PMID: 36096732 DOI: 10.1186/s12876-022-02498-1] [Reference Citation Analysis]
3 Ma Q, Li H, Liao J, Cai Z, Zhang B. Tailored therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Front Pharmacol 2022;13:908202. [DOI: 10.3389/fphar.2022.908202] [Reference Citation Analysis]
4 Jiang Z, Qian X, Wang Z, Dong Y, Pan Y, Zhang Z, Wang S. Antibiotic resistance of Helicobacter pylori isolated from patients in Nanjing, China: A cross-section study from 2018 to 2021. Front Cell Infect Microbiol 2022;12:970630. [DOI: 10.3389/fcimb.2022.970630] [Reference Citation Analysis]
5 Li P, Jin J, Chen Y, Ma J, Du Q, Han Y. Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy. Front Microbiol 2022;13:973975. [DOI: 10.3389/fmicb.2022.973975] [Reference Citation Analysis]
6 Ang D, Koo SH. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs-authors' reply. Aliment Pharmacol Ther 2022;56:1076-7. [PMID: 35995742 DOI: 10.1111/apt.17167] [Reference Citation Analysis]
7 Gisbert JP, Hunt RH. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs. Aliment Pharmacol Ther 2022;56:1074-5. [PMID: 35995738 DOI: 10.1111/apt.17142] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Schneider C, Venerito M. Gastroduodenale Ulkuskrankheit und Helicobacter pylori. Dtsch Med Wochenschr 2022;147:1103-8. [DOI: 10.1055/a-1640-2830] [Reference Citation Analysis]
9 Wernly S, Semmler G, Völkerer A, Flamm M, Aigner E, Niederseer D, Wernly B, Datz C. Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter? Helicobacter 2022;:e12928. [PMID: 36046921 DOI: 10.1111/hel.12928] [Reference Citation Analysis]
10 Shatila M, Thomas AS. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. JCM 2022;11:5086. [DOI: 10.3390/jcm11175086] [Reference Citation Analysis]
11 Ma S, Guo X, Wang C, Yin Y, Xu G, Chen H, Qi X. Association of Barrett's esophagus with Helicobacter pylori infection: a meta-analysis. Ther Adv Chronic Dis 2022;13:20406223221117971. [PMID: 36034104 DOI: 10.1177/20406223221117971] [Reference Citation Analysis]
12 Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Lu NH, Zhu Y. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. Helicobacter 2022;:e12923. [PMID: 36036087 DOI: 10.1111/hel.12923] [Reference Citation Analysis]
13 Resina E, Donday MG, Martínez-domínguez SJ, Laserna-mendieta EJ, Lanas Á, Lucendo AJ, Sánchez-luengo M, Alcaide N, Fernández-salazar L, De La Peña-negro L, Bujanda L, Arbulo MGD, Alcedo J, Pérez-aísa Á, Rodríguez R, Hermida S, Brenes Y, Nyssen OP, Gisbert JP. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study. JCM 2022;11:5077. [DOI: 10.3390/jcm11175077] [Reference Citation Analysis]
14 Karbalaei M, Keikha M. Statistical proof of Helicobacter pylori eradication in preventing metachronous gastric cancer after endoscopic resection in an East Asian population. World J Gastrointest Surg 2022; 14(8): 867-873 [DOI: 10.4240/wjgs.v14.i8.867] [Reference Citation Analysis]
15 Lei C, Gong D, Zhuang B, Zhang Z. Alterations in the gastric microbiota and metabolites in gastric cancer: An update review. Front Oncol 2022;12:960281. [DOI: 10.3389/fonc.2022.960281] [Reference Citation Analysis]
16 Kim SJ, Jee SR, Park MI, Jung K, Kim GH, Lee MW, Lee J, Jang JS, Koh M; Busan and Gyeongnam Society of Helicobacter and Upper Gastrointestinal Research. A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations. Medicine (Baltimore) 2022;101:e30069. [PMID: 35984159 DOI: 10.1097/MD.0000000000030069] [Reference Citation Analysis]
17 Takeuchi H, Okamoto A. Helicobacter pylori Infection and Chronic Immune Thrombocytopenia. JCM 2022;11:4822. [DOI: 10.3390/jcm11164822] [Reference Citation Analysis]
18 Bordin D, Morozov S, Plavnik R, Bakulina N, Voynovan I, Skibo I, Isakov V, Bakulin I, Andreev D, Maev I. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter 2022;:e12924. [PMID: 35971900 DOI: 10.1111/hel.12924] [Reference Citation Analysis]
19 Zhou J, Liu C, Liu B, Wang Y, Benghezal M, Marshall BJ, Tang H, Li H. Association of serum pepsinogens and gastrin-17 with Helicobacter pylori infection assessed by urea breath test. Front Cell Infect Microbiol 2022;12:980399. [DOI: 10.3389/fcimb.2022.980399] [Reference Citation Analysis]
20 Lu J, Van Hoang D, Hayashi Y, Hashimoto M, Kubo S, Kajio H, Mizoue T, Siemianowicz K. Negative-High Titer of Helicobacter pylori Antibody and Lipid Profiles. BioMed Research International 2022;2022:1-5. [DOI: 10.1155/2022/9984255] [Reference Citation Analysis]
21 Feng T, Zheng Z, Xu J, Cao P, Gao S, Yu X. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China. Int J Environ Res Public Health 2022;19:9986. [PMID: 36011621 DOI: 10.3390/ijerph19169986] [Reference Citation Analysis]
22 Keikha M, Karbalaei M. Prevalence of antibiotic heteroresistance associated with Helicobacter pylori infection: A systematic review and meta-analysis. Microb Pathog 2022;170:105720. [PMID: 35964816 DOI: 10.1016/j.micpath.2022.105720] [Reference Citation Analysis]
23 Zhang Y, Wang M, Zhang K, Zhang J, Yuan X, Zou G, Cao Z, Zhang C. 6'-O-Galloylpaeoniflorin attenuates Helicobacter pylori-associated gastritis via modulating Nrf2 pathway. Int Immunopharmacol 2022;111:109122. [PMID: 35964411 DOI: 10.1016/j.intimp.2022.109122] [Reference Citation Analysis]
24 Qin S, Wang X, Li S, Tan C, Zeng X, Wu M, Peng Y, Wang L, Wan X. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study. Front Public Health 2022;10:955120. [DOI: 10.3389/fpubh.2022.955120] [Reference Citation Analysis]
25 Fernandez-caso B, Miqueleiz A, Valdez VB, Alarcón T. Are molecular methods helpful for the diagnosis of Helicobacter pylori infection and for the prediction of its antimicrobial resistance? Front Microbiol 2022;13:962063. [DOI: 10.3389/fmicb.2022.962063] [Reference Citation Analysis]
26 Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022:gutjnl-2022-327745. [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745] [Reference Citation Analysis]
27 Han YY, Long H, Lin Y, He Q, Chen WG, Ding XW, Zhou L, An P, Wang F, Zhang ZY, Hu YL, Li PY. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter 2022. [PMID: 35939559 DOI: 10.1111/hel.12922] [Reference Citation Analysis]
28 Zhong Z, Zhan B, Xu B, Gao H. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization. Helicobacter 2022;:e12916. [PMID: 35939537 DOI: 10.1111/hel.12916] [Reference Citation Analysis]
29 Arismendi Sosa AC, Mariani ML, Vega AE, Penissi AB. Extra virgin olive oil inhibits Helicobacter pylori growth in vitro and the development of mice gastric mucosa lesions in vivo. Front Microbiol 2022;13:961597. [DOI: 10.3389/fmicb.2022.961597] [Reference Citation Analysis]
30 Ang D. Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply. Aliment Pharmacol Ther 2022;56:754-5. [PMID: 35879904 DOI: 10.1111/apt.17133] [Reference Citation Analysis]
31 Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022;117:1221-30. [PMID: 35509128 DOI: 10.14309/ajg.0000000000001828] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Jiang Y, Huang L, Zhou L. Association between obesity and helicobacter pylori infection. Nutrition Clinique et Métabolisme 2022. [DOI: 10.1016/j.nupar.2022.07.003] [Reference Citation Analysis]
33 Chtourou L, Moalla M, Mnif B, Smaoui H, Gdoura H, Boudabous M, Mnif L, Amouri A, Hammami A, Tahri N. Prevalence of Helicobacter pylori resistance to clarithromycin in Tunisia. J Med Microbiol 2022;71. [PMID: 36006691 DOI: 10.1099/jmm.0.001561] [Reference Citation Analysis]
34 Nkuize M, De Wit S. Issues Related to the Treatment of H. pylori Infection in People Living with HIV and Receiving Antiretrovirals. Microorganisms 2022;10:1541. [DOI: 10.3390/microorganisms10081541] [Reference Citation Analysis]
35 Yu XC, Shao QQ, Ma J, Yu M, Zhang C, Lei L, Zhou Y, Chen WC, Zhang W, Fang XH, Zhu YZ, Wu G, Wang XM, Han SY, Sun PC, Ding SZ. Family-based Helicobacter pylori infection status and transmission pattern in central China, and its clinical implications for related disease prevention. World J Gastroenterol 2022; 28(28): 3706-3719 [DOI: 10.3748/wjg.v28.i28.3706] [Reference Citation Analysis]
36 Yu M, Ma J, Song XX, Shao QQ, Yu XC, Khan MN, Qi YB, Hu RB, Wei PR, Xiao W, Jia BL, Cheng YB, Kong LF, Chen CL, Ding SZ. Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation. World J Gastroenterol 2022; 28(28): 3682-3694 [DOI: 10.3748/wjg.v28.i28.3682] [Reference Citation Analysis]
37 García-Gómez-Heras S, Fernández-Aceñero MJ, González G, Bolaños-Muñoz ML, Franco-Rodríguez R, Paredes-González J, Ruiz-Tovar J. Involvement of Helicobacter pylori in Preoperative Gastric Findings on a Bariatric Population. Int J Environ Res Public Health 2022;19:9088. [PMID: 35897458 DOI: 10.3390/ijerph19159088] [Reference Citation Analysis]
38 Pichon M, Freche B, Burucoa C. Guided Treatment of Helicobacter pylori Infections with Non-Invasive PCR Tests-The Glory Days of Primary Care? J Clin Med 2022;11:4320. [PMID: 35893411 DOI: 10.3390/jcm11154320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Pichon M, Luzarraga V, Burucoa C. Mutations Associated to Antibiotic-Resistant Helicobacter pylori: It Is Time to Validate Sequencing Observations. JCM 2022;11:4293. [DOI: 10.3390/jcm11154293] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Benigno TGDS, Ribeiro Junior HL, Azevedo OGR, Pinheiro RF, Oliveira RTG, Maciel FS, Oliveira EL, Queiroz DMM, Braga LLBC. Clarithromycin-resistant H. pylori primary strains and virulence genotypes in the Northeastern region of Brazil. Rev Inst Med Trop Sao Paulo 2022;64:e47. [PMID: 35858038 DOI: 10.1590/S1678-9946202264047] [Reference Citation Analysis]
41 Wang Y, Tang J, Zhou S, Liang TT, Wang FF, Ning H. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review - Are They Potential Eradication Regimens? Infect Drug Resist 2022;15:3733-49. [PMID: 35859911 DOI: 10.2147/IDR.S371131] [Reference Citation Analysis]
42 De Francesco V, Alicante S, Amato A, Frazzoni L, Lombardi G, Manfredi G, Monica F, Sferrazza S, Vassallo R, Germanà B, Pasquale L, Annibale B, Cadoni S. Quality performance measures in upper gastrointestinal endoscopy for lesion detection: Italian AIGO-SIED-SIGE joint position statement. Dig Liver Dis 2022:S1590-8658(22)00581-3. [PMID: 35871984 DOI: 10.1016/j.dld.2022.06.028] [Reference Citation Analysis]
43 Shi X, Wang C, Meng F, Ma S, Xu G, Liu T, Guo X, Li H, Qi X. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med 2022. [PMID: 35860966 DOI: 10.1080/00325481.2022.2105094] [Reference Citation Analysis]
44 Ferreira R, Sousa C, Gonçalves RFS, Pinheiro AC, Oleastro M, Wagemans J, Lavigne R, Figueiredo C, Azeredo J, Melo LDR. Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori. Int J Mol Sci 2022;23:7885. [PMID: 35887231 DOI: 10.3390/ijms23147885] [Reference Citation Analysis]
45 Yang J, Yang H, Dai Y, Jiang Y, Long Y, Zeng J, Ma X. Evidence construction of Chinese herbal formulae for the treatment of H. pylori positive peptic ulcer: A Bayesian network Meta-analysis. Phytomedicine 2022;105:154327. [PMID: 35905565 DOI: 10.1016/j.phymed.2022.154327] [Reference Citation Analysis]
46 Wang YK, Zhou JL, Meng NL, Zhu CY, Wang SN, Chen XD. How Does Helicobacter pylori Infection Cause Gastric Mucosal Atrophy. Infect Drug Resist 2022;15:3619-29. [PMID: 35837536 DOI: 10.2147/IDR.S355981] [Reference Citation Analysis]
47 Kim SE, Hwang JH. Management of Helicobacter pylori Infection: A Comparison between Korea and the United States. Gut Liver 2022;16:503-14. [PMID: 35843686 DOI: 10.5009/gnl210224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens 2022;11:786. [DOI: 10.3390/pathogens11070786] [Reference Citation Analysis]
49 Romano M, Gravina AG, Eusebi LH, Pellegrino R, Palladino G, Frazzoni L, Dajti E, Gasbarrini A, Di Mario F, Zagari RM; Members of SIGE., Members of SIED National Council. Management of Helicobacter pylori infection: Guidelines of the Italian society of gastroenterology (SIGE) and the Italian society of digestive endoscopy (SIED). Dig Liver Dis 2022:S1590-8658(22)00558-8. [PMID: 35831212 DOI: 10.1016/j.dld.2022.06.019] [Reference Citation Analysis]
50 Qu P, Liu X, Xia X, Xie X, Luo J, Cheng S, Chi J, Liu P, Li H, Zhao W, Yang H, Xu C. Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study. Front Cell Infect Microbiol 2022;12:903002. [DOI: 10.3389/fcimb.2022.903002] [Reference Citation Analysis]
51 Song Y, Liu X, Cheng W, Li H, Zhang D. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci Rep 2022;12:11542. [PMID: 35798837 DOI: 10.1038/s41598-022-15839-7] [Reference Citation Analysis]
52 Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, Hungin P, Overshott R, Vasant DH, Rudd S, Winning RC, Corsetti M, Ford AC. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 2022:gutjnl-2022-327737. [PMID: 35798375 DOI: 10.1136/gutjnl-2022-327737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Geisler T, Poli S, Huber K, Rath D, Aidery P, Kristensen SD, Storey RF, Ball A, Collet JP, Berg JT. Resumption of Antiplatelet Therapy after Major Bleeding. Thromb Haemost 2022. [PMID: 35785817 DOI: 10.1055/s-0042-1750419] [Reference Citation Analysis]
54 Buran T, Sürücüoğlu S, Kurutepe S, Gazi H. Recent trends in the antibiotic resistance of Helicobacter pylori in patient with dyspepsia. Medicine (Baltimore) 2022;101:e29801. [PMID: 35777028 DOI: 10.1097/MD.0000000000029801] [Reference Citation Analysis]
55 Fallone CA. The Current Role of Vonoprazan in Helicobacter pylori Treatment. Gastroenterology 2022:S0016-5085(22)00738-7. [PMID: 35780869 DOI: 10.1053/j.gastro.2022.06.076] [Reference Citation Analysis]
56 Lai C, Lin T, Huang M, Li S, Wu H, Chiu Y, Yang C, Chiu C, Lai H. Gut Commensal Parabacteroides goldsteinii MTS01 Alters Gut Microbiota Composition and Reduces Cholesterol to Mitigate Helicobacter pylori-Induced Pathogenesis. Front Immunol 2022;13:916848. [DOI: 10.3389/fimmu.2022.916848] [Reference Citation Analysis]
57 Sisto F, Carradori S, D’alessandro S, Santo N, Lattuada N, Haynes RK, Taramelli D, Grande R. In Vitro Activity of the Arylaminoartemisinin GC012 against Helicobacter pylori and Its Effects on Biofilm. Pathogens 2022;11:740. [DOI: 10.3390/pathogens11070740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Dai YY, Qin C, Huang GR, Qin YC, Huang YY, Huang YQ, Zhao LJ. Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori. Antimicrob Agents Chemother 2022;:e0007322. [PMID: 35758720 DOI: 10.1128/aac.00073-22] [Reference Citation Analysis]
59 Abdelmalek S, Shokry K, Hamed W, Abdelnaser M, Aboubakr A, Elenin SA, Ali M, Mostafa M, Abou-Okada M. The validity evaluation of different 16srRNA gene primers for helicobacter detection urgently requesting to design new specific primers. Sci Rep 2022;12:10737. [PMID: 35750699 DOI: 10.1038/s41598-022-14600-4] [Reference Citation Analysis]
60 Grosso R, de-Paz M. Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations. Pharmaceutics 2022;14:1340. [DOI: 10.3390/pharmaceutics14071340] [Reference Citation Analysis]
61 Li L, Ni J, Sun S, Zha X, Li R, He C. Clinical applicability of a new scoring system for population-based screening and risk factors of gastric cancer in the Wannan region. BMC Gastroenterol 2022;22:306. [PMID: 35739473 DOI: 10.1186/s12876-022-02384-w] [Reference Citation Analysis]
62 Zhou G, Song C, Liu X, Zhao J, Meng D. Insight into the Potential of Meehania fargesii var. Radicans against Hp-Induced Gastric Carcinoma Based on Phytochemical and Molecular Docking Studies. Chem Biodivers 2022;:e202200383. [PMID: 35739622 DOI: 10.1002/cbdv.202200383] [Reference Citation Analysis]
63 Raderer M, Kiesewetter B, Mayerhoefer ME. Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment? Expert Rev Hematol 2022;:1-7. [PMID: 35695746 DOI: 10.1080/17474086.2022.2089110] [Reference Citation Analysis]
64 Daelemans S, Deseck V, Levy EI, Vandenplas Y. Are pro- and/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review. Eur J Pediatr 2022. [PMID: 35726032 DOI: 10.1007/s00431-022-04523-7] [Reference Citation Analysis]
65 Fernández-Salazar L, Campillo A, Rodrigo L, Pérez-Aisa Á, González-Santiago JM, Segarra Ortega X, Denkovski M, Brglez Jurecic N, Bujanda L, Gómez Rodríguez BJ, Ortuño J, Georgopoulos S, Jonaitis L, Puig I, P Nyssen O, Megraud F, O'Morain C, P Gisbert J. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). J Clin Med 2022;11:3544. [PMID: 35743627 DOI: 10.3390/jcm11123544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 35716370 DOI: 10.1111/jgh.15917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ma J, Yu M, Shao QQ, Yu XC, Zhang C, Zhao JB, Yuan L, Qi YB, Hu RB, Wei PR, Xiao W, Chen Q, Jia BL, Chen CL, Lu H, Ding SZ. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention. Helicobacter 2022;:e12911. [PMID: 35706404 DOI: 10.1111/hel.12911] [Reference Citation Analysis]
68 Pinho AS, Seabra CL, Nunes C, Reis S, L Martins MC, Parreira P. Helicobacter pylori biofilms are disrupted by nanostructured lipid carriers: A path to eradication? J Control Release 2022;348:489-98. [PMID: 35654169 DOI: 10.1016/j.jconrel.2022.05.050] [Reference Citation Analysis]
69 Nyssen OP, Espada M, Gisbert JP. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol 2022;13:913436. [DOI: 10.3389/fmicb.2022.913436] [Reference Citation Analysis]
70 Zhang X, Sang S, Guan Q, Tao H, Wang Y, Liu C. Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model. Front Immunol 2022;13:894206. [DOI: 10.3389/fimmu.2022.894206] [Reference Citation Analysis]
71 Zou Y, Chen X, Sun Y, Li P, Xu M, Fang P, Zhang S, Yuan G, Deng X, Hu H. Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria. J Control Release 2022;348:370-85. [PMID: 35662575 DOI: 10.1016/j.jconrel.2022.05.044] [Reference Citation Analysis]
72 Parra-Sepúlveda C, Sánchez-Alonzo K, Olivares-Muñoz J, Gutiérrez-Zamorano C, Smith CT, Carvajal RI, Sáez-Carrillo K, González C, García-Cancino A. Consumption of a Gelatin Supplemented with the Probiotic Strain Limosilactobacillus fermentum UCO-979C Prevents Helicobacter pylori Infection in a Young Adult Population Achieved. Foods 2022;11:1668. [PMID: 35741866 DOI: 10.3390/foods11121668] [Reference Citation Analysis]
73 Azab ET, Thabit AK, Mckee S, Al-qiraiqiri A. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens? Gut Pathog 2022;14. [DOI: 10.1186/s13099-022-00502-3] [Reference Citation Analysis]
74 Wasielica-berger J, Gugnacki P, Mlynarczyk M, Rogalski P, Swidnicka-siergiejko A, Antonowicz S, Krzyzak M, Maslach D, Dabrowski A, Daniluk J. Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. IJERPH 2022;19:6921. [DOI: 10.3390/ijerph19116921] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther 2022. [PMID: 35665947 DOI: 10.1111/apt.17070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
76 Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, Chen X, Li X, Tang Y, Li X, Hao Q, Liu J, Sang T, Bo Y, Bai F. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother 2022;:e0218821. [PMID: 35652644 DOI: 10.1128/aac.02188-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Shu X, Xie Y, Lu N, Zhu Y. Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Front Cell Infect Microbiol 2022;12:881968. [DOI: 10.3389/fcimb.2022.881968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Valladales-Restrepo LF, Constain-Mosquera CA, Hoyos-Guapacha MA, Hoyos-Guapacha KL, Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE. Study of the indications for macrolide prescriptions in a Colombian population. Biomedica 2022;42:302-14. [PMID: 35867923 DOI: 10.7705/biomedica.6116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Motta-raymundo A, Rosmaninho P, Santos DF, Ferreira RD, Silva SP, Ferreira C, Sousa AE, Silva SL. Contribution of Helicobacter pylori to the Inflammatory Complications of Common Variable Immunodeficiency. Front Immunol 2022;13:834137. [DOI: 10.3389/fimmu.2022.834137] [Reference Citation Analysis]
80 Keçeli Başaran M, Zengin NŞ. Can Saccharomyces boulardii treat and eradicate Helicobacter pylori among children instead of bismuth? J Health Sci Med / JHSM 2022;5:912-6. [DOI: 10.32322/jhsm.1084384] [Reference Citation Analysis]
81 Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, Suzuki H, Kanai T, Masaoka T. Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen. Helicobacter. [DOI: 10.1111/hel.12900] [Reference Citation Analysis]
82 Kouhsari E, Sadeghifard N, Khadiv A, Sayadi H, Amiriani T, Ghafourian S, Valadbeigi H, Krutova M. Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2022;21:19. [PMID: 35596211 DOI: 10.1186/s12941-022-00509-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kostenko VV, Mouzykantov AA, Baranova NB, Boulygina EA, Markelova MI, Khusnutdinova DR, Trushin MV, Chernova OA, Chernov VM. Development of Resistance to Clarithromycin and Amoxicillin-Clavulanic Acid in Lactiplantibacillus plantarum In Vitro Is Followed by Genomic Rearrangements and Evolution of Virulence. Microbiol Spectr 2022;:e0236021. [PMID: 35579444 DOI: 10.1128/spectrum.02360-21] [Reference Citation Analysis]
84 Niu M, Zhou Y, Xie Y, Li X, Tian Y, Yao L, Li X, Gao H, Bai F. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori. Front Pharmacol 2022;13:771876. [PMID: 35571120 DOI: 10.3389/fphar.2022.771876] [Reference Citation Analysis]
85 Wang Y, Wu S, Wang L, Wang Y, Liu D, Fu Y, Xie Y. The Activity of Liposomal Linolenic Acid Against Helicobacter pylori In Vitro and Its Impact on Human Fecal Bacteria. Front Cell Infect Microbiol 2022;12:865320. [DOI: 10.3389/fcimb.2022.865320] [Reference Citation Analysis]
86 Sijmons D, Guy AJ, Walduck AK, Ramsland PA. Helicobacter pylori and the Role of Lipopolysaccharide Variation in Innate Immune Evasion. Front Immunol 2022;13:868225. [DOI: 10.3389/fimmu.2022.868225] [Reference Citation Analysis]
87 Razuka-ebela D, Polaka I, Daugule I, Parshutin S, Santare D, Ebela I, Rudzite D, Vangravs R, Herrero R, Young Park J, Leja M. Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study. Diagnostics 2022;12:1166. [DOI: 10.3390/diagnostics12051166] [Reference Citation Analysis]
88 Guo Y, Cao X, Guo G, Zhou M, Yu B. Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis. Front Cell Infect Microbiol 2022;12:899248. [DOI: 10.3389/fcimb.2022.899248] [Reference Citation Analysis]
89 Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor A, Yamamoto H. Changes in gastric morphology during long-term use of vonoprazan compared to proton pump inhibitors. smedj 2022;63:283-7. [DOI: 10.11622/smedj.2022076] [Reference Citation Analysis]
90 He C, Kong F, Chai X, Zou C, Zhu X, Zhao D, Tan LTH. Effect of Probiotic-Assisted Eradication of cagA+/vacA s1m1 Helicobacter pylori on Intestinal Flora. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/8607671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Burra P, Bretthauer M, Buti Ferret M, Dugic A, Fracasso P, Leja M, Matysiak Budnik T, Michl P, Ricciardiello L, Seufferlein T, van Leerdam M, Botos A. Digestive cancer screening across Europe. United European Gastroenterol J 2022. [PMID: 35474447 DOI: 10.1002/ueg2.12230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Xu WF, Wang Y, Huang H, Wu JW, Che Y, Ding CJ, Zhang Q, Cao WL, Cao LJ. Octreotide-based therapies effectively protect mice from acute and chronic gastritis. Eur J Pharmacol 2022;:174976. [PMID: 35487253 DOI: 10.1016/j.ejphar.2022.174976] [Reference Citation Analysis]
93 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y. Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter. [DOI: 10.1111/hel.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Knoop RF, Gaertner PC, Petzold G, Amanzada A, Ellenrieder V, Neesse A, Bremer SCB, Kunsch S, Mascellino MT. Systematic Retesting for Helicobacter pylori: The Potential Overestimation of Suppressive Conditions. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/5380001] [Reference Citation Analysis]
95 Geng T, Yu ZS, Zhou XX, Liu B, Zhang HH, Li ZY. Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China. Eur J Pediatr 2022. [PMID: 35469031 DOI: 10.1007/s00431-022-04456-1] [Reference Citation Analysis]
96 Dawod HM. A prospective study for evaluating the effect of gastric targeted biopsy sampling with I‐scan optical enhancement on the diagnostic yield of CLOtest for Helicobacter pylori infection. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.621] [Reference Citation Analysis]
97 Esposito G, Dottori L, Pivetta G, Ligato I, Dilaghi E, Lahner E. Pernicious Anemia: The Hematological Presentation of a Multifaceted Disorder Caused by Cobalamin Deficiency. Nutrients 2022;14:1672. [PMID: 35458234 DOI: 10.3390/nu14081672] [Reference Citation Analysis]
98 Venerito M, Sulzer S, Jechorek D. [Clinical management of autoimmune gastritis]. Dtsch Med Wochenschr 2022;147:451-9. [PMID: 35405749 DOI: 10.1055/a-1520-3562] [Reference Citation Analysis]
99 Choe Y, Kim JS, Choi HH, Kim DB, Park JM, Oh JH, Kim TH, Cheung DY, Chung WC, Kim BW, Kim SS. The Influence of Past Metronidazole Exposure on the Outcome of Helicobacter pylori Eradication. Front Microbiol 2022;13:857569. [PMID: 35401472 DOI: 10.3389/fmicb.2022.857569] [Reference Citation Analysis]
100 Jiang F, Guo CG, Cheung KS, Li B, Law SYK, Leung WK. Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study. Helicobacter 2022;:e12893. [PMID: 35411663 DOI: 10.1111/hel.12893] [Reference Citation Analysis]
101 Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev 2022;:e0025821. [PMID: 35404105 DOI: 10.1128/cmr.00258-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Song Z, Chen Y, Lu H, Zeng Z, Wang W, Liu X, Zhang G, Du Q, Xia X, Li C, Jiang S, Wu T, Li P, He S, Zhu Y, Zhang G, Xu J, Li Y, Huo L, Lan C, Miao Y, Jiang H, Chen P, Shi L, Tuo B, Zhang D, Jiang K, Wang J, Yao P, Huang X, Yang S, Wang X, Zhou L. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study. Helicobacter 2022;:e12889. [PMID: 35363917 DOI: 10.1111/hel.12889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol 2022;16:341-57. [PMID: 35315732 DOI: 10.1080/17474124.2022.2056015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2022;77:360-7. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Hou C, Yin F, Wang S, Zhao A, Li Y, Liu Y. Helicobacter pylori Biofilm-Related Drug Resistance and New Developments in Its Anti-Biofilm Agents. IDR 2022;Volume 15:1561-71. [DOI: 10.2147/idr.s357473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
106 Luo W, Wang Q, Zhang X, Gu D, Zhang W, Yuan C. Evaluation of the diagnostic value of FliD, a Helicobacter pylori flagellar protein. Jpn J Infect Dis 2022. [PMID: 35354706 DOI: 10.7883/yoken.JJID.2021.795] [Reference Citation Analysis]
107 Vrebalov Cindro P, Bukic J, Pranić S, Leskur D, Rušić D, Šešelja Perišin A, Božić J, Vuković J, Modun D. Did an introduction of CONSORT for abstracts guidelines improve reporting quality of randomised controlled trials' abstracts on Helicobacter pylori infection? Observational study. BMJ Open 2022;12:e054978. [PMID: 35354625 DOI: 10.1136/bmjopen-2021-054978] [Reference Citation Analysis]
108 Guo Z, Tian S, Wang W, Zhang Y, Li J, Lin R. Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections. Front Microbiol 2022;13:861626. [PMID: 35330762 DOI: 10.3389/fmicb.2022.861626] [Reference Citation Analysis]
109 Ouyang Y, Zhang W, He C, Zhu Y, Lu N, Hu Y. Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022;9:844915. [PMID: 35402425 DOI: 10.3389/fmed.2022.844915] [Reference Citation Analysis]
110 Niknam R, Lankarani KB, Moghadami M, Taghavi SA, Zahiri L, Fallahi MJ. The association between helicobacter pylori infection and erosive gastroesophageal reflux disease; a cross-sectional study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07278-6] [Reference Citation Analysis]
111 Nyssen OP, Vaira D, Saracino IM, Fiorini G, Caldas M, Bujanda L, Pellicano R, Keco-Huerga A, Pabón-Carrasco M, Oblitas Susanibar E, Di Leo A, Losurdo G, Pérez-Aísa Á, Gasbarrini A, Boltin D, Smith S, Phull P, Rokkas T, Lamarque D, Cano-Català A, Puig I, Mégraud F, O'Morain C, Gisbert JP. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). J Clin Med 2022;11:1658. [PMID: 35329984 DOI: 10.3390/jcm11061658] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Shu C, Tian J, Si X, Xie X, Li B, Li D. Blueberry anthocyanin extracts protect against Helicobacter pylori-induced peptic epithelium injuries both in vitro and in vivo: the key role of MAPK/NF-κB pathway. Eur J Nutr 2022. [PMID: 35288783 DOI: 10.1007/s00394-022-02830-1] [Reference Citation Analysis]
113 Calado CRC. Antigenic and conserved peptides from diverse Helicobacter pylori antigens. Biotechnol Lett. [DOI: 10.1007/s10529-022-03238-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. J Clin Pharm Ther 2022. [PMID: 35247003 DOI: 10.1111/jcpt.13637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Klang E, Soffer S, Barash Y, Shachar E, Lahat A. Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications. CEG 2022;Volume 15:51-8. [DOI: 10.2147/ceg.s342048] [Reference Citation Analysis]
116 Guan JL, Hu YL, An P, He Q, Long H, Zhou L, Chen ZF, Xiong JG, Wu SS, Ding XW, Luo HS, Li PY. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial. Pharmacotherapy 2022;42:224-32. [PMID: 35075679 DOI: 10.1002/phar.2662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Durazzo M, Ferro A. Helicobacter pylori and nutrition: main highlights. Gazz Med Ital - Arch Sci Med 2021;180. [DOI: 10.23736/s0393-3660.21.04740-9] [Reference Citation Analysis]
118 Hallur V, Panigrahi M, Sable M, Ghosh M, Mohanty S, Purkait S, Praharaj A. Low clarithromycin resistance in virulent Helicobacter pylori from dyspeptic patients at a tertiary care centre in Odisha. Indian Journal of Medical Microbiology 2022. [DOI: 10.1016/j.ijmmb.2022.02.008] [Reference Citation Analysis]
119 Suerbaum S, Coombs N, Patel L, Pscheniza D, Rox K, Falk C, Gruber AD, Kershaw O, Chhatwal P, Brönstrup M, Bilitewski U, Josenhans C. Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model. mBio 2022;:e0375521. [PMID: 35227071 DOI: 10.1128/mbio.03755-21] [Reference Citation Analysis]
120 Han L, Shu X, Wang J. Helicobacter pylori-Mediated Oxidative Stress and Gastric Diseases: A Review. Front Microbiol 2022;13:811258. [PMID: 35211104 DOI: 10.3389/fmicb.2022.811258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
121 Do AD, Su CH, Hsu YM. Antagonistic Activities of Lactobacillus rhamnosus JB3 Against Helicobacter pylori Infection Through Lipid Raft Formation. Front Immunol 2021;12:796177. [PMID: 35095872 DOI: 10.3389/fimmu.2021.796177] [Reference Citation Analysis]
122 Pichon M, Freche B, Burucoa C. New Strategy for the Detection and Treatment of Helicobacter pylori Infections in Primary Care Guided by a Non-Invasive PCR in Stool: Protocol of the French HepyPrim Study. J Clin Med 2022;11:1151. [PMID: 35268242 DOI: 10.3390/jcm11051151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
123 Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit–risk approach? World J Gastroenterol 2022; 28(7): 766-774 [DOI: 10.3748/wjg.v28.i7.766] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Zhou BG, Yan XL, Wan LY, Zhang Q, Li B, Ai YW. Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials. Helicobacter 2022;:e12869. [PMID: 35178810 DOI: 10.1111/hel.12869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere (Groza) F, Cavalu S. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics 2022;12:508. [DOI: 10.3390/diagnostics12020508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
126 Bordin DS, Shengelia MI, Ivanova VA, Voynovan IN. The history of the discovery of the Helicobacter pylori. Terapevticheskii arkhiv 2022;94:283-8. [DOI: 10.26442/00403660.2022.02.201377] [Reference Citation Analysis]
127 Maev IV, Mkrtumyan AM, Bektemirova LG, Andreev DN, Dicheva DT. The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus. Terapevticheskii arkhiv 2022;94:209-15. [DOI: 10.26442/00403660.2022.02.201372] [Reference Citation Analysis]
128 Yang H, Yang WJ, Hu B. Gastric epithelial histology and precancerous conditions. World J Gastrointest Oncol 2022; 14(2): 396-412 [DOI: 10.4251/wjgo.v14.i2.396] [Reference Citation Analysis]
129 Lopes-de-Campos D, Leal Seabra C, Pinto RM, Adam Słowiński M, Sarmento B, Nunes C, Cristina L Martins M, Reis S. Targeting and Killing the Ever-Challenging Ulcer Bug. Int J Pharm 2022;:121582. [PMID: 35176334 DOI: 10.1016/j.ijpharm.2022.121582] [Reference Citation Analysis]
130 Fatemi Khader M, Pourmahdi Borujeni M, Moori Bakhtiari N, Avizeh R. An exploratory study on the presence of Helicobacter heilmannii and Helicobacter billis in the faces of companion dogs. Veterinary Medicine & Sci. [DOI: 10.1002/vms3.765] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Zha J, Li YY, Qu JY, Yang XX, Han ZX, Zuo X. Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter 2022;:e12880. [PMID: 35150600 DOI: 10.1111/hel.12880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Li H, Shen Y, Song X, Tang X, Hu R, Marshall BJ, Tang H, Benghezal M. Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing. Helicobacter 2022;:e12873. [PMID: 35151236 DOI: 10.1111/hel.12873] [Reference Citation Analysis]
133 Ho C, Liu T, Lin Y, Chen Y, Chen M, Wang H, Liou T. Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection. Microorganisms 2022;10:415. [DOI: 10.3390/microorganisms10020415] [Reference Citation Analysis]
134 Li Y, Huang Z, Shang Y, Xie X, Yang R, Chen H, Wang Z, Xue L, Pang R, Zhang J, Ding Y, Chen M, Wang J, Chen J, Wu Q. Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori : A whole‐genome sequencing‐based study in Southern China. Helicobacter. [DOI: 10.1111/hel.12879] [Reference Citation Analysis]
135 Wang Y, Gong X, Liu D, Zeng R, Zhou L, Sun X, Liu D, Xie Y. Characteristics of Helicobacter pylori Heteroresistance in Gastric Biopsies and Its Clinical Relevance. Front Cell Infect Microbiol 2022;11:819506. [DOI: 10.3389/fcimb.2021.819506] [Reference Citation Analysis]
136 Shi Y, Zheng H, Wang M, Ding S. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter 2022;:e12878. [PMID: 35112435 DOI: 10.1111/hel.12878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Tran TT, Nguyen AT, Quach DT, Pham DT, Cao NM, Nguyen UT, Dang AN, Tran MA, Quach LH, Tran KT, Le NQ, Ung VV, Vo MN, Nguyen DT, Ngo KD, Tran TL, Nguyen VT. Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam. BMC Microbiol 2022;22:41. [PMID: 35114945 DOI: 10.1186/s12866-022-02463-8] [Reference Citation Analysis]
138 Shen C, Li C, Lv M, Dai X, Gao C, Li L, Zhang Q, Pan W, Liu C, Han S, Zhang Y, Ding S, Deng H, Yao Y, Xu J, Wei M, Shi H, Yuan P, Yang X, Jian Y, Shan J, Liu Y, Chen Z, Deng X, Liu F, Deng L, Zhong X, Li H, He S, Chen L, Liu G, Xu H, Zhong Y, Shi H, Ren J; Multi-Center Clinical Research Collaboration Group of Sichuan Provincial H. pylori Scientific Group, Sichuan Provincial Medical Association. The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas. Ann Med 2022;54:426-35. [PMID: 35098820 DOI: 10.1080/07853890.2022.2031269] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, Liatsos C, Giouleme O, Koustenis K, Veretanos C, Stogiannou D, Moutzoukis M, Poutakidis C, Mylonas II, Tseti I, Mantzaris GJ. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 2022;14:632. [PMID: 35276991 DOI: 10.3390/nu14030632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
140 Yan J, Peng C, Chen P, Zhang W, Jiang C, Sang S, Zhu W, Yuan Y, Hong Y, Yao M. In-vitro anti-Helicobacter pylori activity and preliminary mechanism of action of Canarium album Raeusch. fruit extracts. J Ethnopharmacol 2022;283:114578. [PMID: 34464702 DOI: 10.1016/j.jep.2021.114578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
141 Brennan DE, O'Morain C, McNamara D, Smith SM. Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success. World J Gastrointest Pathophysiol 2022; 13(1): 34-40 [DOI: 10.4291/wjgp.v13.i1.34] [Reference Citation Analysis]
142 Komarov AL, Shahmatova OO, Korobkova VV, Kurilina EV, Shuleshova AG, Panchenko EP. Gastric mucosa condition in patients with coronary artery disease and high risk of gastrointestinal bleeding (register REGATTA-1). Terapevticheskii arkhiv 2022;93:1457-62. [DOI: 10.26442/00403660.2021.12.201224] [Reference Citation Analysis]
143 Wang K, Lou D, Dai W, Fu R, Ma Z. Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis. J Med Microbiol 2022;71. [PMID: 35041577 DOI: 10.1099/jmm.0.001490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Subsomwong P, Doohan D, Fauzia KA, Akada J, Matsumoto T, Yee TT, Htet K, Waskito LA, Tuan VP, Uchida T, Matsuhisa T, Yamaoka Y. Next-Generation Sequencing-Based Study of Helicobacter pylori Isolates from Myanmar and Their Susceptibility to Antibiotics. Microorganisms 2022;10:196. [DOI: 10.3390/microorganisms10010196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Sharaf M, Arif M, Hamouda HI, Khan S, Abdalla M, Shabana S, Rozan HE, Khan TU, Chi Z, Liu C. Preparation, urease inhibition mechanisms, and anti-Helicobacter pylori activities of hesperetin-7-rhamnoglucoside. Curr Res Microb Sci 2022;3:100103. [PMID: 35024644 DOI: 10.1016/j.crmicr.2021.100103] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
146 Peng C, Sang S, Shen X, Zhang W, Yan J, Chen P, Jiang C, Yuan Y, Zhu W, Yao M. In vitro anti-Helicobacter pylori activity of Syzygium aromaticum and the preliminary mechanism of action. J Ethnopharmacol 2022;:114995. [PMID: 35032584 DOI: 10.1016/j.jep.2022.114995] [Reference Citation Analysis]
147 Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut 2022:gutjnl-2021-326583. [PMID: 35022266 DOI: 10.1136/gutjnl-2021-326583] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
148 Losurdo G, Lacavalla I, Russo F, Riezzo G, Brescia IV, Rendina M, Ierardi E, Di Leo A. Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. Antibiotics (Basel) 2022;11:78. [PMID: 35052955 DOI: 10.3390/antibiotics11010078] [Reference Citation Analysis]
149 Rokkas T, Georgopoulos S, Michopoulos S, Ntouli V, Liatsos C, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg). Ann Gastroenterol 2022;35:42-7. [PMID: 34987287 DOI: 10.20524/aog.2021.0670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Yang JC, Kao JY. Treatment considerations in Helicobacter pylori management. Aliment Pharmacol Ther 2022;55 Suppl 1:S22-8. [PMID: 34989432 DOI: 10.1111/apt.16652] [Reference Citation Analysis]
151 Skrebinska S, Megraud F, Daugule I, Santare D, Isajevs S, Liepniece-Karele I, Bogdanova I, Rudzite D, Vangravs R, Kikuste I, Vanags A, Tolmanis I, Savcenko S, Alix C, Herrero R, Park JY, Leja M. Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection? Diagnostics (Basel) 2022;12:133. [PMID: 35054298 DOI: 10.3390/diagnostics12010133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
152 Xiang W, Wang R, Bai D, Yu T, Chen X; on behalf of the SIGES Research Groups. Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES). Nutrition and Cancer. [DOI: 10.1080/01635581.2021.2022168] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Haumaier F, Schneider-Fuchs A, Backert S, Vieth M, Sterlacci W, Wöhrl BM. Rapid Detection of Quinolone Resistance Mutations in gyrA of Helicobacter pylori by Real-Time PCR. Pathogens 2022;11:59. [PMID: 35056007 DOI: 10.3390/pathogens11010059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Nabavi-Rad A, Sadeghi A, Asadzadeh Aghdaei H, Yadegar A, Smith SM, Zali MR. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Gut Microbes 2022;14:2108655. [PMID: 35951774 DOI: 10.1080/19490976.2022.2108655] [Reference Citation Analysis]
155 Zhang L, Lan Y, Wang Q, Si X, Zhang Y. Application of minocycline in patients with Helicobacter pylori infection allergic to penicillin. Food Sci Technol 2022;42:e67121. [DOI: 10.1590/fst.67121] [Reference Citation Analysis]
156 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]
157 Fonseca DR, Moura A, Leiro V, Silva-Carvalho R, Estevinho BN, Seabra CL, Henriques PC, Lucena M, Teixeira C, Gomes P, Parreira P, Martins MCL. Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomater 2022;137:186-98. [PMID: 34634508 DOI: 10.1016/j.actbio.2021.09.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
158 Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. J Global Infect Dis 2022;14:99. [DOI: 10.4103/jgid.jgid_13_22] [Reference Citation Analysis]
159 Kim Y, Choi IJ. Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening to Helicobacter pylori Eradication in Korea. J Gastric Cancer 2022;22:e22. [DOI: 10.5230/jgc.2022.22.e22] [Reference Citation Analysis]
160 Wang L, Yao H, Tong T, Lau K, Leung SY, Ho JWK, Leung WK. Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies. Helicobacter. [DOI: 10.1111/hel.12871] [Reference Citation Analysis]
161 Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Reference Citation Analysis]
162 Yang Y, Ji R, Zhao X, Cao X, Wang Q, Jiang Q, Zhang Y, Zheng W, Wu X, Yang A. Alterations in Gastric Mucosal Microbiota in Gastric Carcinogenesis: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:754959. [PMID: 34926502 DOI: 10.3389/fmed.2021.754959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Spiegel M, Krzyżek P, Dworniczek E, Adamski R, Sroka Z. In Silico Screening and In Vitro Assessment of Natural Products with Anti-Virulence Activity against Helicobacter pylori. Molecules 2021;27:20. [PMID: 35011255 DOI: 10.3390/molecules27010020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
164 Wang C, Yin Y, Wang L, Guo X, Liu L, Qi X. Association between Helicobacter pylori infection and irritable bowel syndrome: a systematic review and meta-analysis. Postgrad Med J 2021:postgradmedj-2021-141127. [PMID: 34930813 DOI: 10.1136/postgradmedj-2021-141127] [Reference Citation Analysis]
165 Cho JH, Jin SY, Park S. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34883037 DOI: 10.1080/14787210.2022.2017280] [Reference Citation Analysis]
166 Cao Y, Zhang J, Liu Y, Zhang L, Wang L, Wang J, Qi Y, Lv H, Liu J, Huo L, Wei X, Shi Y. The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial. Medicine (Baltimore) 2021;100:e27923. [PMID: 34918639 DOI: 10.1097/MD.0000000000027923] [Reference Citation Analysis]
167 Zhao Y, Li Y, Luan Z, Ma C, Yang L, Zhang W, Shi C. Establishment of a TaqMan-MGB probe multiplex real-time PCR system for one-step levofloxacin and clarithromycin resistant Helicobacter pylori detection. J Microbiol Methods 2021;192:106393. [PMID: 34919971 DOI: 10.1016/j.mimet.2021.106393] [Reference Citation Analysis]
168 Kohoutova D, Banks M, Bures J. Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer. Cancers (Basel) 2021;13:6242. [PMID: 34944861 DOI: 10.3390/cancers13246242] [Reference Citation Analysis]
169 Kim Y, Chung WC. Bismuth-containing Standard Triple Therapy the First-line Eradication Therapy for Helicobacter pylori. Korean J Helicobacter Up Gastrointest Res 2021;21:354-8. [DOI: 10.7704/kjhugr.2021.0027] [Reference Citation Analysis]
170 Kim TJ, Lee H. Benefits of Helicobacter pylori Eradication on Extragastric Diseases. Korean J Helicobacter Up Gastrointest Res 2021;21:275-86. [DOI: 10.7704/kjhugr.2021.0041] [Reference Citation Analysis]
171 Reyes D, Ortiz J, Fuentes-López E, Budnik S, Gandara V, Gallardo A, Seydewitz MF, Candia R, Ignacio Vargas J, Rollan MP, Godoy J, Rollan A, Mansilla R, Arenas A, Chahuán J, Espino A, Pizarro M, Riquelme A. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterol Hepatol 2021:S0210-5705(21)00320-4. [PMID: 34890721 DOI: 10.1016/j.gastrohep.2021.11.010] [Reference Citation Analysis]
172 Zhao Y, Yang Y, Aruna, Xiao J, Song J, Huang T, Li S, Kou J, Huang L, Ji D, Xiong S, Peng W, Xu S, Cheng B. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne) 2021;8:776955. [PMID: 34869495 DOI: 10.3389/fmed.2021.776955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Hofmann R, Bäck M. Gastro-Cardiology: A Novel Perspective for the Gastrocardiac Syndrome. Front Cardiovasc Med 2021;8:764478. [PMID: 34869678 DOI: 10.3389/fcvm.2021.764478] [Reference Citation Analysis]
174 Wu SR, Liu J, Zhang LF, Wang N, Zhang LY, Wu Q, Liu JY, Shi YQ. Lamb’s tripe extract and vitamin B12 capsule plus celecoxib reverses intestinal metaplasia and atrophy: A retrospective cohort study. World J Clin Cases 2021; 9(34): 10472-10483 [PMID: 35004979 DOI: 10.12998/wjcc.v9.i34.10472] [Reference Citation Analysis]
175 Ren S, Cai P, Liu Y, Wang T, Zhang Y, Li Q, Gu Y, Wei L, Yan C, Jin G. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34862656 DOI: 10.1111/jgh.15751] [Reference Citation Analysis]
176 Taha-Mehlitz S, Mongelli F, Sykora M, Scheiwiller A, Diebold J, Metzger J, Gass JM. Routine histopathologic examination of the resected specimen after laparoscopic sleeve gastrectomy - what can be expected? Acta Chir Belg 2021;121:380-5. [PMID: 32644013 DOI: 10.1080/00015458.2020.1794335] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
178 Dao LV, Dao HV, Nguyen HT, Vu VT, Tran ATN, Dat VQ, Hoang LB, Nguyen HTV, Nguyen TD. Helicobacter pylori infection and eradication outcomes among Vietnamese patients in the same households: Findings from a non-randomized study. PLoS One 2021;16:e0260454. [PMID: 34818349 DOI: 10.1371/journal.pone.0260454] [Reference Citation Analysis]
179 Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, Tsai PY, Hsu PI, Wu IC, Wu JY, Wu DC, Yu FJ, Kuo CH. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc 2021:S0929-6646(21)00483-6. [PMID: 34836662 DOI: 10.1016/j.jfma.2021.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Luu MN, Quach DT, Hiyama T. Screening and surveillance for gastric cancer: Does family history play an important role in shaping our strategy? Asia Pac J Clin Oncol 2021. [PMID: 34811928 DOI: 10.1111/ajco.13704] [Reference Citation Analysis]
181 Lazebnik LB, Golovanova EV, Volel BA, Korochanskaya NV, Lyalyukova EA, Mokshina MV, Mekhtiev SN, Mekhtieva OA, Metsaeva ZV, Petelin DS, Simanenkov VI, Sitkin SI, Cheremushkin SV, Chernogorova MV, Khavkin АI. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. jour 2021. [DOI: 10.31146/1682-8658-ecg-192-8-5-117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
182 Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics (Basel) 2021;11:2113. [PMID: 34829460 DOI: 10.3390/diagnostics11112113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
183 Schulz C, Kalali B, Link A, Gerhard M, Malfertheiner P. New rapid Helicobacter pylori blood test based on dual detection of FliD and CagA antibodies for on-site testing. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01220-9. [PMID: 34793965 DOI: 10.1016/j.cgh.2021.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Guo CG, Jiang F, Cheung KS, Li B, Ooi PH, Leung WK. Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. J Antimicrob Chemother 2021:dkab415. [PMID: 34791274 DOI: 10.1093/jac/dkab415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Zagari RM, Romano M, Frazzoni L, Marasco G, Dajti E, Arcidiacono PG, Armuzzi A, Biagi F, Cannizzaro R, Cavestro GM, Ciacci C, Monica F, Peralta S, Radaelli F, Bazzoli F. Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. Helicobacter 2021;:e12862. [PMID: 34766392 DOI: 10.1111/hel.12862] [Reference Citation Analysis]
186 Sulo P, Šipková B. DNA diagnostics for reliable and universal identification of Helicobacter pyloriWorld J Gastroenterol 2021; 27(41): 7100-7112 [PMID: 34887630 DOI: 10.3748/wjg.v27.i41.7100] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
187 Nayebi A, Navashenaq JG, Soleimani D, Nachvak SM. Probiotic supplementation: A prospective approach in the treatment of COVID-19. Nutr Health 2021;:2601060211049631. [PMID: 34747257 DOI: 10.1177/02601060211049631] [Reference Citation Analysis]
188 Zheng S, Hu R, Yu X, Chen L, BinrongWang, Qin Y, Zhou X, Wang Y, Huang B, Fang H, Liu P. Development of a time-resolved fluorescence immunoassay based on immunomagnetic beads for gastrin-17. J Immunol Methods 2021;499:113179. [PMID: 34728217 DOI: 10.1016/j.jim.2021.113179] [Reference Citation Analysis]
189 Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, Kawai Y, Fujimiya T, Takeuchi H, Unezaki S, Kawai T. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol 2021;12:759249. [PMID: 34721043 DOI: 10.3389/fphar.2021.759249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kim JS, Park JC, Lee JY, Ahn JY, Kang SH, Yang HJ, Kim SJ, Joo MK, Park JM. Long-Term Clinical Outcomes of Gastric MALT Lymphoma: A Nationwide Multicenter Study in Korea. Front Oncol 2021;11:681689. [PMID: 34722238 DOI: 10.3389/fonc.2021.681689] [Reference Citation Analysis]
191 Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS, Shin WG. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 2021;70:2066-75. [PMID: 33975868 DOI: 10.1136/gutjnl-2020-323845] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
192 Gomes RD, Anaya K, Galdino AB, Oliveira JP, Gama MA, Medeiros CA, Gavioli EC, Porto ALF, Rangel AH. Bovine colostrum: A source of bioactive compounds for prevention and treatment of gastrointestinal disorders. NFS Journal 2021;25:1-11. [DOI: 10.1016/j.nfs.2021.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Chen MJ, Chen CC, Huang YC, Tseng CC, Hsu JT, Lin YF, Fang YJ, Wu MS, Liou JM; Taiwan Gastrointestinal Disease, Helicobacter Consortium. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial. Helicobacter 2021;26:e12857. [PMID: 34708471 DOI: 10.1111/hel.12857] [Reference Citation Analysis]
194 Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2021;:e12860. [PMID: 34708484 DOI: 10.1111/hel.12860] [Reference Citation Analysis]
195 Nikbazm R, Rahimi Z, Moradi Y, Alipour M, Shidfar F. The effect of cranberry supplementation on Helicobacter pylori eradication in H. pylori positive subjects: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2021;:1-10. [PMID: 34670631 DOI: 10.1017/S0007114521004256] [Reference Citation Analysis]
196 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
197 Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Front Med (Lausanne) 2021;8:713908. [PMID: 34660627 DOI: 10.3389/fmed.2021.713908] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
198 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. Management of Helicobacter pylori infection in the pediatric age. An Pediatr (Engl Ed) 2021;95:383.e1-9. [PMID: 34642127 DOI: 10.1016/j.anpede.2021.05.004] [Reference Citation Analysis]
200 Mao LQ, Zhou YL, Wang SS, Chen L, Hu Y, Yu LM, Xu JM, Lyu B. Impact of Helicobacter pylori eradication on the gastric microbiome. Gut Pathog 2021;13:60. [PMID: 34645495 DOI: 10.1186/s13099-021-00460-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
201 Grad C, Pop A, Gaborean E, Grad S, Dumitrascu D. Value of GastroPanel in the diagnosis of atrophic gastritis. Exp Ther Med 2021;22:1347. [PMID: 34630701 DOI: 10.3892/etm.2021.10782] [Reference Citation Analysis]
202 Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, Chen Y. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter 2021;26:e12856. [PMID: 34628695 DOI: 10.1111/hel.12856] [Reference Citation Analysis]
203 Loor A, Dumitrascu DL, Surdea-Blaga T, Leucuta DC, David L. Helicobacter pylori infection and positive Rome IV criteria for functional dyspepsia in Romanian medical students. J Med Life 2021;14:492-7. [PMID: 34621372 DOI: 10.25122/jml-2021-0163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol 2021;36:3308-13. [PMID: 34622504 DOI: 10.1111/jgh.15700] [Reference Citation Analysis]
205 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
206 Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, Akyıldız E, Topbaş M, Özgür O, Arslan M. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol 2020;31:221-33. [PMID: 32343234 DOI: 10.5152/tjg.2020.18631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
208 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
209 Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, Kılınç A, Uygun A. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020;31:234-8. [PMID: 32343235 DOI: 10.5152/tjg.2020.18974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
210 Liu F, Yu J, Zhang YX, Li F, Liu Q, Zhou Y, Huang S, Fang H, Xiao Z, Liao L, Xu J, Wu XY, Wu F. High-throughput tandem-microwell assay for ammonia repositions FDA-Approved drugs to inhibit Helicobacter pylori urease. FASEB J 2021;35:e21967. [PMID: 34613630 DOI: 10.1096/fj.202100465RR] [Reference Citation Analysis]
211 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021;70:1815-22. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
212 Tsimpiris A, Grigoriadis A, Tsolianos I, Moschos I, Goulis DG, Kouklakis G. Periodontitis and Helicobacter pylori Infection: Eradication and Periodontal Therapy Combination. Eur J Dent 2021. [PMID: 34598295 DOI: 10.1055/s-0041-1731928] [Reference Citation Analysis]
213 Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, Tack J, Accarino A, Barbara G, Bor S, Coffin B, Corsetti M, De Schepper H, Dumitrascu D, Farmer A, Gourcerol G, Hauser G, Hausken T, Karamanolis G, Keszthelyi D, Malagelada C, Milosavljevic T, Muris J, O'Morain C, Papathanasopoulos A, Pohl D, Rumyantseva D, Sarnelli G, Savarino E, Schol J, Sheptulin A, Smet A, Stengel A, Storonova O, Storr M, Törnblom H, Vanuytsel T, Velosa M, Waluga M, Zarate N, Zerbib F; ESNM FD Consensus Group. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. Neurogastroenterol Motil 2021;33:e14238. [PMID: 34586707 DOI: 10.1111/nmo.14238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
214 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
215 Chen HY, Hu Y, Lu NH, Zhu Y. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;12:1-12. [PMID: 33031021 DOI: 10.1080/19490976.2020.1809331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
216 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
217 Wojtyś MI, Jaźwiec R, Kazazić S, Leščić Ašler I, Knežević P, Aleksić Sabo V, Luić M, Jagusztyn-Krynicka EK, Bzowska A. A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori. Appl Microbiol Biotechnol 2021;105:7949-67. [PMID: 34562116 DOI: 10.1007/s00253-021-11510-9] [Reference Citation Analysis]
218 Durazzo M, Adriani A, Fagoonee S, Saracco GM, Pellicano R. Helicobacter pylori and Respiratory Diseases: 2021 Update. Microorganisms 2021;9:2033. [PMID: 34683354 DOI: 10.3390/microorganisms9102033] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
219 Yang H, Wei B, Hu B. Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer. Inflamm Res 2021;70:1015-26. [PMID: 34549319 DOI: 10.1007/s00011-021-01501-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
220 Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases 2021;9:66. [PMID: 34698140 DOI: 10.3390/diseases9040066] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
221 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Yano T, Lefor AK, Yamamoto H. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapy. Scand J Gastroenterol 2021;:1-6. [PMID: 34547219 DOI: 10.1080/00365521.2021.1975310] [Reference Citation Analysis]
222 Salillas S, Galano-Frutos JJ, Mahía A, Maity R, Conde-Giménez M, Anoz-Carbonell E, Berlamont H, Velazquez-Campoy A, Touati E, Mamat U, Schaible UE, Gálvez JA, Díaz-de-Villegas MD, Haesebrouck F, Aínsa JA, Sancho J. Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies. Int J Mol Sci 2021;22:10137. [PMID: 34576300 DOI: 10.3390/ijms221810137] [Reference Citation Analysis]
223 Pouw RE, Barret M, Biermann K, Bisschops R, Czakó L, Gecse KB, de Hertogh G, Hucl T, Iacucci M, Jansen M, Rutter M, Savarino E, Spaander MCW, Schmidt PT, Vieth M, Dinis-Ribeiro M, van Hooft JE. Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1174-88. [PMID: 34535035 DOI: 10.1055/a-1611-5091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
224 Lucero Y, Lagomarcino AJ, Torres JP, Roessler P, Mamani N, George SA, Huerta N, González M, O'Ryan G M. Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial. Helicobacter 2021;26:e12853. [PMID: 34528337 DOI: 10.1111/hel.12853] [Reference Citation Analysis]
225 Gidlöf S. Is the scalpel the greatest proof of the failure of medicine? Acta Obstet Gynecol Scand 2021;100:1755. [PMID: 34528712 DOI: 10.1111/aogs.14257] [Reference Citation Analysis]
226 El Shahawy MS, Shady ZM, Gaafar A. Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of Helicobacter pylori infection. Arab J Gastroenterol 2021;22:209-14. [PMID: 34521593 DOI: 10.1016/j.ajg.2021.08.002] [Reference Citation Analysis]
227 Miftahussurur M, Waskito LA, Fauzia KA, Mahmudah I, Doohan D, Adnyana IK, Khomsan A, Ratnasari N, Rezkitha YAA. Overview of Helicobacter pylori Infection in Indonesia: What Distinguishes It from Countries with High Gastric Cancer Incidence? Gut Liver 2021;15:653-65. [PMID: 32616679 DOI: 10.5009/gnl20019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Sánchez-Alonzo K, Arellano-Arriagada L, Castro-Seriche S, Parra-Sepúlveda C, Bernasconi H, Benavidez-Hernández H, Campos VL, Sáez K, Smith CT, García-Cancino A. Temperatures Outside the Optimal Range for Helicobacter pylori Increase Its Harboring within Candida Yeast Cells. Biology (Basel) 2021;10:915. [PMID: 34571792 DOI: 10.3390/biology10090915] [Reference Citation Analysis]
229 Guillemard E, Poirel M, Schäfer F, Quinquis L, Rossoni C, Keicher C, Wagner F, Szajewska H, Barbut F, Derrien M, Malfertheiner P. A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy. Nutrients 2021;13:3171. [PMID: 34579049 DOI: 10.3390/nu13093171] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
230 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
231 Kang S, Cho S. Proton Pump Inhibitors and Gastric Cancer. Korean J Helicobacter Up Gastrointest Res 2021;21:173-9. [DOI: 10.7704/kjhugr.2021.0010] [Reference Citation Analysis]
232 Jo HG, Kim YS. Helicobacter pylori Eradication Therapy-associated Diarrhea. Korean J Helicobacter Up Gastrointest Res 2021;21:203-14. [DOI: 10.7704/kjhugr.2021.0037] [Reference Citation Analysis]
233 Yasukawa K. Redox-based theranostics of gastric ulcer using nitroxyl radicals. Antioxid Redox Signal 2021. [PMID: 34498915 DOI: 10.1089/ars.2021.0104] [Reference Citation Analysis]
234 Chen HY, Hu Y, Xu XB, Zhou YA, Li NS, He C, Xie C, Lu NH, Zhu Y. Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2. Helicobacter 2021;26:e12849. [PMID: 34490965 DOI: 10.1111/hel.12849] [Reference Citation Analysis]
235 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Huang X, Liu Y, Lin Z, Wu B, Nong G, Chen Y, Lu Y, Ji X, Zhou X, Suo B, Chen Q, Wei J. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One 2021;16:e0256225. [PMID: 34473713 DOI: 10.1371/journal.pone.0256225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Chen Y, Yuan H, Ye H, Shi Z, Deng X, Zhang X, Hou X. Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial. Microbiologyopen 2021;10:e1172. [PMID: 33650799 DOI: 10.1002/mbo3.1172] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
238 Sukri A, Lopes BS, Hanafiah A. The Emergence of Multidrug-Resistant Helicobacter pylori in Southeast Asia: A Systematic Review on the Trends and Intervention Strategies Using Antimicrobial Peptides. Antibiotics (Basel) 2021;10:1061. [PMID: 34572643 DOI: 10.3390/antibiotics10091061] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
239 Hellström PM, Benno P, Malfertheiner P. Gastrointestinal bleeding in patients with Helicobacter pylori and dual platelet inhibition after myocardial infarction. Lancet Gastroenterol Hepatol 2021;6:684-5. [PMID: 34391514 DOI: 10.1016/S2468-1253(21)00192-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Wang Y, Guo X, Zhou S, Wang L, Fang Y, Xing L, Zhao Y, Zhang LP, Qiu H, Zeng J, Gu Y. Selective photodynamic inactivation of Helicobacter pylori by a cationic benzylidene cyclopentanone photosensitizer - an in vitro and ex vivo study. J Photochem Photobiol B 2021;223:112287. [PMID: 34454316 DOI: 10.1016/j.jphotobiol.2021.112287] [Reference Citation Analysis]
241 Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, Liu Z, Yin Z, Xue Y, Zhou L. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter 2021;26:e12848. [PMID: 34448282 DOI: 10.1111/hel.12848] [Reference Citation Analysis]
242 Wang S, Ye F, Sheng Y, Yu W, Liu Y, Liu D, Zhang K. Development and Validation of Nomograms to Predict Operative Link for Gastritis Assessment Any-Stage and Stages III-IV in the Chinese High-Risk Gastric Cancer Population. Front Med (Lausanne) 2021;8:724566. [PMID: 34447771 DOI: 10.3389/fmed.2021.724566] [Reference Citation Analysis]
243 Mousavi T, Nikfar S, Abdollahi M. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opin Pharmacother 2021;:1-27. [PMID: 34435515 DOI: 10.1080/14656566.2021.1959914] [Reference Citation Analysis]
244 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter Upper Gastrointestinal Research. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition.Gut Liver. 2020;14:707-726. [PMID: 33191311 DOI: 10.5009/gnl20246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
245 Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel) 2021;10:1028. [PMID: 34572610 DOI: 10.3390/antibiotics10091028] [Reference Citation Analysis]
246 Sarajlic P, Simonsson M, Jernberg T, Bäck M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2021:pvab059. [PMID: 34423350 DOI: 10.1093/ehjcvp/pvab059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
247 Yao X, Xiao S, Zhou L. Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication. Helicobacter 2021;26:e12846. [PMID: 34414638 DOI: 10.1111/hel.12846] [Reference Citation Analysis]
248 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Weng CY, Xu JL, Sun SP, Wang KJ, Lv B. Helicobacter pylori eradication: Exploring its impacts on the gastric mucosa. World J Gastroenterol 2021; 27(31): 5152-5170 [PMID: 34497441 DOI: 10.3748/wjg.v27.i31.5152] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Varon C, Azzi-Martin L, Khalid S, Seeneevassen L, Ménard A, Spuul P. Helicobacters and cancer, not only gastric cancer? Semin Cancer Biol 2021:S1044-579X(21)00219-4. [PMID: 34425210 DOI: 10.1016/j.semcancer.2021.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
251 Long Parma D, Schmidt S, Muñoz E, Ramirez AG. Gastric adenocarcinoma burden and late-stage diagnosis in Latino and non-Latino populations in the United States and Texas, during 2004-2016: A multilevel analysis. Cancer Med 2021;10:6468-79. [PMID: 34409764 DOI: 10.1002/cam4.4175] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
252 Manu P, Rogozea LM, Sandor V, Dumitraşcu DL. Pharmacological Management of Peptic Ulcer: A Century of Expert Opinions in Cecil Textbook of Medicine. Am J Ther 2021;28:e552-9. [PMID: 34469923 DOI: 10.1097/MJT.0000000000001439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Kornoukhova LA, Emanuel VL, Denisov NL, Nikonov EL. Helicobacter pylori infection: place of serological and cultural diagnostics in clinical guidelines. Klin Lab Diagn 2021;66:496-501. [PMID: 34388321 DOI: 10.51620/0869-2084-2021-66-8-496-501] [Reference Citation Analysis]
254 Kako S, Iwaya Y, Nagaya T, Hara D, Okamura T, Iwaya M, Kurasawa S, Kato S, Nakayama Y, Akamatsu T, Umemura T. Clinicopathological features of nodular gastritis in three classes of age. Helicobacter 2021;:e12845. [PMID: 34396629 DOI: 10.1111/hel.12845] [Reference Citation Analysis]
255 Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol 2021;12:e00391. [PMID: 34397042 DOI: 10.14309/ctg.0000000000000391] [Reference Citation Analysis]
256 Yakovenko EP, Strokova TV, Iakovenko AV, Ivanov AN, Soluyanova IP, Vasilyev NN. A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>. Terapevticheskii arkhiv 2021;93:916-22. [DOI: 10.26442/00403660.2021.08.200996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Reference Citation Analysis]
258 Lee JW, Kim N, Nam RH, Jang JY, Choi Y, Lee DH. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance. Helicobacter 2021;:e12844. [PMID: 34382277 DOI: 10.1111/hel.12844] [Reference Citation Analysis]
259 Bordin DS, Voynovan IN, Andreev DN, Maev IV. Current Helicobacter pylori Diagnostics. Diagnostics (Basel) 2021;11:1458. [PMID: 34441392 DOI: 10.3390/diagnostics11081458] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
260 Caldas M, Pérez-Aisa Á, Tepes B, Keco-Huerga A, Bujanda L, Lucendo AJ, Rodrigo L, Vaira D, Fernández-Salazar L, Huguet JM, Pérez-Lasala J, Jurecic NB, Fadeenko G, Barrio J, Areia M, Ortuño J, Pellicano R, Leja M, Molina-Infante J, Bogomolov P, Alekseenko S, Domínguez-Cajal M, Gómez-Camarero J, Ntouli V, Martínez-Domínguez SJ, Ruiz-Zorrilla R, Núñez O, Sarsenbaeva AS, Almela P, Phull P, Espada M, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; the Hp-EuReg Investigators. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics (Basel) 2021;10:965. [PMID: 34439015 DOI: 10.3390/antibiotics10080965] [Reference Citation Analysis]
261 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Clinical Guidelines for Drug-induced Peptic Ulcer, 2020 Revised Edition]. Korean J Gastroenterol 2020;76:108-33. [PMID: 32969360 DOI: 10.4166/kjg.2020.76.3.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
262 Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, Shin YW, Suh YJ, Kim H. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol 2021;56:1017-22. [PMID: 34369255 DOI: 10.1080/00365521.2021.1948606] [Reference Citation Analysis]
263 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
264 Mestrovic A, Bozic J, Vukojevic K, Tonkic A. Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms. Medicina (Kaunas) 2021;57:803. [PMID: 34441009 DOI: 10.3390/medicina57080803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03338-2. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
266 Hafiz TA, D'Sa JL, Zamzam S, Dionaldo MLV, Mubaraki MA, Tumala RB. Helicobacter pylori Infection: Comparison of Knowledge between Health Science and Non-Health Science University Students. Int J Environ Res Public Health 2021;18:8173. [PMID: 34360466 DOI: 10.3390/ijerph18158173] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
267 Homolak J, Nikolić M, Potoč D, Živković M, Bakula D, Budimir I, Pavić I, Hrabar D, Ljubičić N, Vražić D. The onset of ulcerative colitis upon Helicobacter pylori eradication in a 72-year-old woman: report of a rare case with a 3-year follow-up. BMC Gastroenterol 2021;21:303. [PMID: 34332529 DOI: 10.1186/s12876-021-01876-5] [Reference Citation Analysis]
268 Gong L, El-Omar EM. Application of molecular techniques in Helicobacter pylori detection: limitations and improvements. Helicobacter 2021;:e12841. [PMID: 34333819 DOI: 10.1111/hel.12841] [Reference Citation Analysis]
269 Doohan D, Fauzia KA, Rathnayake J, Lamawansa MD, Waskito LA, Tuan VP, Dashdorj A, Kabamba ET, Phuc BH, Ansari S, Akada J, Matsumoto T, Uchida T, Matsuhisa T, Yamaoka Y. Pepsinogen and Serum IgG Detection Is a Valuable Diagnostic Method for Helicobacter pylori Infection in a Low-Prevalence Country: A Report from Sri Lanka. Diagnostics (Basel) 2021;11:1364. [PMID: 34441303 DOI: 10.3390/diagnostics11081364] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
270 Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z, Zhao S, Zhang Y, Song C, Xie Y. Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis. Helicobacter 2021;:e12839. [PMID: 34318971 DOI: 10.1111/hel.12839] [Reference Citation Analysis]
271 Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
272 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
273 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
274 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
275 Dargenio C, Dargenio VN, Bizzoco F, Indrio F, Francavilla R, Cristofori F. Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection. Medicina (Kaunas) 2021;57:733. [PMID: 34357014 DOI: 10.3390/medicina57070733] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
276 Chapelle N, Péron M, Quénéhervé L, Bourget A, Leroy M, Touchefeu Y, Cauchin E, Coron E, Mosnier JF, Matysiak-Budnik T. Long-Term Follow-up of Gastric Precancerous Lesions in a Low GC Incidence Area. Clin Transl Gastroenterol 2020;11:e00237. [PMID: 33512802 DOI: 10.14309/ctg.0000000000000237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
277 Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
278 Nouri D, Soleimanian Gj N, Ataei F, Mohammadi M. Effects of sex, age, size and location of perforation on the sensitivity of erect chest X-ray for gastroduodenal perforation. Radiography (Lond) 2021;27:1158-61. [PMID: 34247912 DOI: 10.1016/j.radi.2021.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Ouyang Y, Zhu Z, Huang L, Zeng C, Zhang L, Wu WK, Lu N, Xie C. Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020. Helicobacter 2021;:e12835. [PMID: 34258827 DOI: 10.1111/hel.12835] [Reference Citation Analysis]
280 Bustamante-Rengifo JA, Astudillo-Hernández M, Del Pilar Crespo-Ortiz M. Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis. Curr Microbiol 2021;78:3351-71. [PMID: 34251513 DOI: 10.1007/s00284-021-02604-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
281 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
282 Rueda-Robles A, Rubio-Tomás T, Plaza-Diaz J, Álvarez-Mercado AI. Impact of Dietary Patterns on H. pylori Infection and the Modulation of Microbiota to Counteract Its Effect. A Narrative Review. Pathogens 2021;10:875. [PMID: 34358024 DOI: 10.3390/pathogens10070875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Biernat MM, Wróbel T. Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment. Int J Mol Sci 2021;22:7372. [PMID: 34298992 DOI: 10.3390/ijms22147372] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
284 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
285 Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00194. [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
286 Pritchard DM, Bornschein J, Beales I, Beresniak A, Salhi H, Malfertheiner P. Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK. BMJ Open Gastroenterol 2021;8:e000685. [PMID: 34244244 DOI: 10.1136/bmjgast-2021-000685] [Reference Citation Analysis]
287 Sun B, Wang X, McLarnon MED, Ding Y, Liu M, Dai W, Wang G. Higher Prevalence of Non-thyroidal-Illness Syndrome in Elderly Male Patients With Active Helicobacter pylori Infection. Front Med (Lausanne) 2021;8:682116. [PMID: 34307412 DOI: 10.3389/fmed.2021.682116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Ma H, Zhao XH, Zhang LL, Wu LM. Application of WeChat platform in the management of patients infected with Helicobacter pylori. Helicobacter 2021;:e12832. [PMID: 34231948 DOI: 10.1111/hel.12832] [Reference Citation Analysis]
289 Niu ZY, Li SZ, Shi YY, Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol 2021; 27(25): 3913-3924 [PMID: 34321854 DOI: 10.3748/wjg.v27.i25.3913] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
290 Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infect Dis 2021;21:642. [PMID: 34218802 DOI: 10.1186/s12879-021-06356-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
291 Ribaldone DG, Zurlo C, Fagoonee S, Rosso C, Armandi A, Caviglia GP, Saracco GM, Pellicano R. A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. Life (Basel) 2021;11:650. [PMID: 34357021 DOI: 10.3390/life11070650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
292 Bornschein J, Pritchard DM. Myths and misconceptions in the management of Helicobacter pylori infection. Frontline Gastroenterol 2022;13:245-53. [DOI: 10.1136/flgastro-2021-101826] [Reference Citation Analysis]
293 Song X, Lv M, Lv Q, Cui H, Fu J, Huo Y. A novel assay strategy based on isothermal amplification and cascade signal amplified electrochemical DNA sensor for sensitive detection of Helicobacter pylori. Microchemical Journal 2021;166:106243. [DOI: 10.1016/j.microc.2021.106243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
294 Shah SC, Peek RM Jr. Chemoprevention Against Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:519-42. [PMID: 34053637 DOI: 10.1016/j.giec.2021.03.006] [Reference Citation Analysis]
295 Thein W, Po WW, Choi WS, Sohn UD. Autophagy and Digestive Disorders: Advances in Understanding and Therapeutic Approaches. Biomol Ther (Seoul) 2021;29:353-64. [PMID: 34127572 DOI: 10.4062/biomolther.2021.086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
296 Contreras-Omaña R, Escorcia-Saucedo AE, Velarde-Ruiz Velasco JA. Prevalence and impact of antimicrobial resistance in gastrointestinal infections: A review. Rev Gastroenterol Mex (Engl Ed) 2021;86:265-75. [PMID: 34158260 DOI: 10.1016/j.rgmxen.2021.06.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis. Adv Ther 2021;38:3937-47. [PMID: 34091865 DOI: 10.1007/s12325-021-01784-w] [Reference Citation Analysis]
298 Kim J, Wang TC. Helicobacter pylori and Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:451-65. [PMID: 34053633 DOI: 10.1016/j.giec.2021.03.003] [Reference Citation Analysis]
299 González-hormazábal P, Arenas A, Serrano C, Pizarro M, Fuentes-lópez E, Arnold J, Berger Z, Musleh M, Valladares H, Lanzarini E, Jara L, Castro VG, Camargo MC, Riquelme A. Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients. Archives of Medical Research 2021;52:529-34. [DOI: 10.1016/j.arcmed.2021.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116:1220-9. [PMID: 33840725 DOI: 10.14309/ajg.0000000000001246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
301 Dos Santos Viana I, Cordeiro Santos ML, Santos Marques H, Lima de Souza Gonçalves V, Bittencourt de Brito B, França da Silva FA, Oliveira E Silva N, Dantas Pinheiro F, Fernandes Teixeira A, Tanajura Costa D, Oliveira Souza B, Lima Souza C, Vasconcelos Oliveira M, Freire de Melo F. Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape. Expert Rev Vaccines 2021;20:989-99. [PMID: 34139141 DOI: 10.1080/14760584.2021.1945450] [Reference Citation Analysis]
302 Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 DOI: 10.3389/pore.2021.1609863] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
303 Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
304 Akar M, Aydın F, Kayman T, Abay S, Karakaya E. Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing? Turk J Med Sci 2021;51:1445-64. [PMID: 33631868 DOI: 10.3906/sag-2101-69] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
305 Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H. Early genetic diagnosis of clarithromycin resistance in Helicobacter pyloriWorld J Gastroenterol 2021; 27(24): 3595-3608 [PMID: 34239272 DOI: 10.3748/wjg.v27.i24.3595] [Reference Citation Analysis]
306 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. [Management of Helicobacter pylori infection in the pediatric age]. An Pediatr (Barc) 2021:S1695-4033(21)00202-2. [PMID: 34183279 DOI: 10.1016/j.anpedi.2021.05.014] [Reference Citation Analysis]
307 Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, Yang Q, Yu X, Lyu Z, Wu J, Guo H, Leung WK, Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother 2020;75:3391-4. [PMID: 32785699 DOI: 10.1093/jac/dkaa315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
308 Zhang S, Wang X, Wise MJ, He Y, Chen H, Liu A, Huang H, Young S, Tay CY, Marshall BJ, Li X, Chua EG. Mutations of Helicobacter pylori RdxA are mainly related to the phylogenetic origin of the strain and not to metronidazole resistance. J Antimicrob Chemother 2020;75:3152-5. [PMID: 32676634 DOI: 10.1093/jac/dkaa302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
309 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
310 Depoorter L, Vandenplas Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021;13:2176. [PMID: 34202742 DOI: 10.3390/nu13072176] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
311 Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, Vlachou E, Tsibouris P, Alexandrakis G. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol 2020;54:522-7. [PMID: 32028286 DOI: 10.1097/MCG.0000000000001328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
312 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Schmilovitz-Weiss H, Dotan I, Birkenfeld S. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success. J Clin Gastroenterol 2020;54:333-7. [PMID: 31305279 DOI: 10.1097/MCG.0000000000001237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Gastli N, Allain M, Lamarque D, Abitbol V, Billoët A, Collobert G, Coriat R, Terris B, Kalach N, Raymond J. Diagnosis of Helicobacter pylori Infection in a Routine Testing Workflow: Effect of Bacterial Load and Virulence Factors. J Clin Med 2021;10:2755. [PMID: 34201588 DOI: 10.3390/jcm10132755] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
314 Steiner TM, Lettl C, Schindele F, Goebel W, Haas R, Fischer W, Eisenreich W. Substrate usage determines carbon flux via the citrate cycle in Helicobacter pylori. Mol Microbiol 2021. [PMID: 34164854 DOI: 10.1111/mmi.14775] [Reference Citation Analysis]
315 Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Yazawa T, Sasaki B, Tani M, Sato A, Katsura H, Kamada Y, Tani R, Aoyama R, Sasaki Y, Shintaku M, Iwasa Y, Zaima M. Multiple Gastric Carcinomas Associated with Epstein-Barr Virus and Helicobacter pylori: A Thought-Provoking Case. Am J Case Rep 2021;22:e931668. [PMID: 34158469 DOI: 10.12659/AJCR.931668] [Reference Citation Analysis]
316 Jonaitis P, Kupcinskas J, Nyssen OP, Puig I, Gisbert JP, Jonaitis L. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina (Kaunas) 2021;57:642. [PMID: 34201428 DOI: 10.3390/medicina57070642] [Reference Citation Analysis]
317 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. [Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer]. Korean J Gastroenterol 2020;75:264-91. [PMID: 32448858 DOI: 10.4166/kjg.2020.75.5.264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
318 Shah T, Baloch Z, Shah Z, Cui X, Xia X. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases. Int J Mol Sci 2021;22:6597. [PMID: 34202945 DOI: 10.3390/ijms22126597] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
319 Kori M, Le Thi TG, Werkstetter K, Sustmann A, Bontems P, Lopes AI, Oleastro M, Iwanczak B, Kalach N, Misak Z, Cabral J, Homan M, Cilleruelo Pascual ML, Pehlivanoglu E, Casswall T, Urruzuno P, Martinez Gomez MJ, Papadopoulou A, Roma E, Dolinsek J, Rogalidou M, Urbonas V, Chong S, Kindermann A, Miele E, Rea F, Cseh Á, Koletzko S; Helicobacter pylori Working Group of ESPGHAN. Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016. J Pediatr Gastroenterol Nutr 2020;71:476-83. [PMID: 32541200 DOI: 10.1097/MPG.0000000000002816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
320 Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne) 2021;12:639856. [PMID: 34220702 DOI: 10.3389/fendo.2021.639856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
321 Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel) 2021;10:967. [PMID: 34208683 DOI: 10.3390/antiox10060967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
322 Choe AR, Shim KN, Park Y, Song EM, Tae CH, Jung SA. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. J Clin Med 2021;10:2619. [PMID: 34198677 DOI: 10.3390/jcm10122619] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
323 Keller J, Hammer HF, Afolabi PR, Benninga M, Borrelli O, Dominguez-Munoz E, Dumitrascu D, Goetze O, Haas SL, Hauser B, Pohl D, Salvatore S, Sonyi M, Thapar N, Verbeke K, Fox MR; European 13C-breath test group. European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC. United European Gastroenterol J 2021;9:598-625. [PMID: 34128346 DOI: 10.1002/ueg2.12099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
324 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
325 Li Y, Lin R, Jin Y, Jin S, Chen B, Wu X. Genotyping Helicobacter pylori antibiotic resistance - and virulence-associated genes in patients with gastric cancer in Wenzhou, China. Arab J Gastroenterol 2021:S1687-1979(21)00039-3. [PMID: 34120851 DOI: 10.1016/j.ajg.2021.05.017] [Reference Citation Analysis]
326 Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
327 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
328 Kotilea K, Cadranel S, Salame A, Nguyen J, Mahler T, Miendje Deyi VY, Verset L, Bontems P. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter 2021;26:e12825. [PMID: 34101296 DOI: 10.1111/hel.12825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Reference Citation Analysis]
330 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
331 Kato S, Shimizu T, Toyoda S, Gold BD, Ida S, Ishige T, Fujimura S, Kamiya S, Konno M, Kuwabara K, Ushijima K, Yoshimura N, Nakayama Y; Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int 2020;62:1315-31. [PMID: 32657507 DOI: 10.1111/ped.14388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
332 Murray BO, Dawson RA, Alsharaf LM, Anne Winter J. Protective effects of Helicobacter pylori membrane vesicles against stress and antimicrobial agents. Microbiology (Reading) 2020;166:751-8. [PMID: 32463354 DOI: 10.1099/mic.0.000934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
333 Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
334 Yang C, Liu L, Majaw JK, Liang L, Chen Y. Efficacy of Lactobacillus reuteri supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomised controlled trials. Medicine in Microecology 2021;8:100036. [DOI: 10.1016/j.medmic.2021.100036] [Reference Citation Analysis]
335 Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
336 Zhang Y, Feng XY, Li GQ, Xu F, Liu F, Li YY, Deng B. Epidemiological study of Helicobacter pylori infection and its relationship with pathologic changes of the antral mucosa in rural areas of Yangzhou. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 550-556 [DOI: 10.11569/wcjd.v29.i10.550] [Reference Citation Analysis]
337 Jonaitis P, Kupcinskas L, Kupcinskas J. Molecular Alterations in Gastric Intestinal Metaplasia. Int J Mol Sci 2021;22:5758. [PMID: 34071181 DOI: 10.3390/ijms22115758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
338 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 29.0] [Reference Citation Analysis]
339 Vishnu P, Duncan J, Connell N, Cooper N, Lim W, Rodeghiero F, Tomiyama Y, Grace RF, Bakchoul T, Arnold DM; Platelet Immunology Scientific, Standardization Committee. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. J Thromb Haemost 2021;19:287-96. [PMID: 33070448 DOI: 10.1111/jth.15136] [Reference Citation Analysis]
340 Dore MP, Pes GM. What Is New in Helicobacter pylori Diagnosis. An Overview. J Clin Med 2021;10:2091. [PMID: 34068062 DOI: 10.3390/jcm10102091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
341 Sánchez-Alonzo K, Silva-Mieres F, Arellano-Arriagada L, Parra-Sepúlveda C, Bernasconi H, Smith CT, Campos VL, García-Cancino A. Nutrient Deficiency Promotes the Entry of Helicobacter pylori Cells into Candida Yeast Cells. Biology (Basel) 2021;10:426. [PMID: 34065788 DOI: 10.3390/biology10050426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
342 Li Y, Zhong X, Zhang Y, Lu X. Mesenchymal Stem Cells in Gastric Cancer: Vicious but Hopeful. Front Oncol 2021;11:617677. [PMID: 34046337 DOI: 10.3389/fonc.2021.617677] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
343 Wang C, Hu Y, Yang H, Wang S, Zhou B, Bao Y, Huang Y, Luo Q, Yang C, Xie X, Yang S. Function of Non-coding RNA in Helicobacter pylori-Infected Gastric Cancer. Front Mol Biosci 2021;8:649105. [PMID: 34046430 DOI: 10.3389/fmolb.2021.649105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Cui R, Song Z, Suo B, Tian X, Xue Y, Meng L, Niu Z, Jin Z, Zhang H, Zhou L. Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori. Infect Drug Resist 2021;14:1747-56. [PMID: 34012273 DOI: 10.2147/IDR.S305996] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
345 Ramírez-Lázaro MJ, Lario S, Quílez ME, Montserrat A, Bella MR, Junquera F, García-Martínez L, Casalots À, Parra T, Calvet X. Droplet Digital PCR Detects Low-Density Infection in a Significant Proportion of Helicobacter Pylori-Negative Gastric Biopsies of Dyspeptic Patients. Clin Transl Gastroenterol 2020;11:e00184. [PMID: 32568476 DOI: 10.14309/ctg.0000000000000184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
346 Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Hernandez Lemus R, Hernandez Monroy A. Is There Any Relationship Between Helicobacter pylori and Obesity, Metabolic Syndrome, and Non-alcoholic Fatty Liver Disease? Curr Trop Med Rep 2021;8:212-7. [DOI: 10.1007/s40475-021-00240-7] [Reference Citation Analysis]
348 De Francesco V, Zullo A, Gatta L, Manta R, Pavoni M, Saracino IM, Fiorini G, Vaira D. Rescue Therapies for H. pylori Infection in Italy. Antibiotics (Basel) 2021;10:525. [PMID: 34063624 DOI: 10.3390/antibiotics10050525] [Reference Citation Analysis]
349 Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, Tack J, Accarino A, Barbara G, Bor S, Coffin B, Corsetti M, De Schepper H, Dumitrascu D, Farmer A, Gourcerol G, Hauser G, Hausken T, Karamanolis G, Keszthelyi D, Malagelada C, Milosavljevic T, Muris J, O'Morain C, Papathanasopoulos A, Pohl D, Rumyantseva D, Sarnelli G, Savarino E, Schol J, Sheptulin A, Smet A, Stengel A, Storonova O, Storr M, Törnblom H, Vanuytsel T, Velosa M, Waluga M, Zarate N, Zerbib F; ESNM FD Consensus Group. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J 2021;9:307-31. [PMID: 33939891 DOI: 10.1002/ueg2.12061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
350 Migone De Amicis M, Rimondi A, Elli L, Motta I. Acquired Refractory Iron Deficiency Anemia. Mediterr J Hematol Infect Dis 2021;13:e2021028. [PMID: 34007416 DOI: 10.4084/MJHID.2021.028] [Reference Citation Analysis]
351 Coelho MCF, Ribeiro HG, Gomes CGO, Marinho FP, Barbosa AJA, Coelho LGV. HELICOBACTER PYLORI CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE. Arq Gastroenterol 2021;58:39-47. [PMID: 33909795 DOI: 10.1590/S0004-2803.202100000-08] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Dai R, Sag AA, Martin JG, Befera NT, Pabon-Ramos WM, Suhocki PV, Smith TP, Kim CY, Muir AJ, Ronald J. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. Clin Imaging 2021;77:187-92. [PMID: 33940357 DOI: 10.1016/j.clinimag.2021.04.034] [Reference Citation Analysis]
353 Gravina AG, Priadko K, Granata L, Facchiano A, Scidà G, Cerbone R, Ciamarra P, Romano M. Single Capsule Bismuth Quadruple Therapy for Eradication of H. pylori Infection: A Real-Life Study. Front Pharmacol 2021;12:667584. [PMID: 33995097 DOI: 10.3389/fphar.2021.667584] [Reference Citation Analysis]
354 Wang X, Shu X, Li Q, Li Y, Chen Z, Wang Y, Pu K, Zheng Y, Ye Y, Liu M, Ma L, Zhang Z, Wu Z, Zhang F, Guo Q, Ji R, Zhou Y. Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study. Helicobacter 2021;26:e12810. [PMID: 33904635 DOI: 10.1111/hel.12810] [Reference Citation Analysis]
355 Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. J Clin Microbiol 2021;59:e03040-20. [PMID: 33536295 DOI: 10.1128/JCM.03040-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
356 Magni A, Agostoni P, Bonezzi C, Massazza G, Menè P, Savarino V, Fornasari D. Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain Ther 2021. [PMID: 33876393 DOI: 10.1007/s40122-021-00260-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
357 Fathy El Sayed A, Magd Eldin Mohammad Sadek A, Ahmed Ragab Abdelhamid W. Comparison between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Trial. Middle East J Dig Dis 2021;13:223-9. [DOI: 10.34172/mejdd.2021.229] [Reference Citation Analysis]
358 Shen X, Zhang W, Peng C, Yan J, Chen P, Jiang C, Yuan Y, Chen D, Zhu W, Yao M. In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection. Chin Med 2021;16:33. [PMID: 33865425 DOI: 10.1186/s13020-021-00442-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
359 Yulizal OK, Tarigan SB, Isnainul OK, Muttaqin Z. Gastric histopathological features after the administration of omeprazole, amoxicillin, and clarithromycin in gastritis Helicobacter pylori rat model. J Adv Vet Anim Res 2021;8:158-63. [PMID: 33860026 DOI: 10.5455/javar.2021.h498] [Reference Citation Analysis]
360 Li SY, Li J, Dong XH, Teng GG, Zhang W, Cheng H, Gao W, Dai Y, Zhang XH, Wang WH. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021;26:e12804. [PMID: 33860967 DOI: 10.1111/hel.12804] [Reference Citation Analysis]
361 Vasapolli R, Venerito M, Schirrmeister W, Thon C, Weigt J, Wex T, Malfertheiner P, Link A. Inflammatory microRNAs in gastric mucosa are modulated by Helicobacter pylori infection and proton-pump inhibitors but not by aspirin or NSAIDs. PLoS One 2021;16:e0249282. [PMID: 33857171 DOI: 10.1371/journal.pone.0249282] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, Fadgyas-Freyler P, Szénás K, Rugge M, Fassan M, Kiss A, Schaff Z, Röst G, Lotz G. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun 2021;12:2255. [PMID: 33859206 DOI: 10.1038/s41467-021-22557-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
363 Saracino IM, Pavoni M, Zullo A, Fiorini G, Lazzarotto T, Borghi C, Vaira D. Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review. Antibiotics (Basel) 2021;10:437. [PMID: 33919811 DOI: 10.3390/antibiotics10040437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
364 Di Palma A, Alhabdan S, Maeda A, Chetty R, Serra S, Quereshy F, Jackson T, Okrainec A. Preoperative Helicobacter pylori Screening and Treatment in Patients Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2020;30:2816-20. [PMID: 32030613 DOI: 10.1007/s11695-020-04436-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
365 Yang L, Zou A, Wu H, Guo H, Zhang F, Zou B, Wang J. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. Biomed Res Int 2021;2021:6150628. [PMID: 33937401 DOI: 10.1155/2021/6150628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
366 Katsurahara M, Imoto I, Umeda Y, Miura H, Tsuboi J, Yamada R, Yasuma T, Nakamura M, Hamada Y, Inoue H, Tanaka K, Horiki N, Gabazza EC, Takei Y. Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer. Cancers (Basel) 2021;13:1779. [PMID: 33917861 DOI: 10.3390/cancers13081779] [Reference Citation Analysis]
367 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
368 Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, Maulahela H, Akil F, Uwan WB, Siregar G, Fauzia KA, Rezkitha YAA, Rahman A, Wibawa IDN, Saudale AMJ, Richardo M, Sugihartono T, Chomariyati A, Bramantoro T, Uchida T, Yamaoka Y. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology (Basel) 2021;10:300. [PMID: 33917299 DOI: 10.3390/biology10040300] [Reference Citation Analysis]
369 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
370 Sugimoto M, Murata M, Iwata E, Nagata N, Itoi T, Kawai T. Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population. J Clin Med 2021;10:1434. [PMID: 33916067 DOI: 10.3390/jcm10071434] [Reference Citation Analysis]
371 Chautard R, Malka D, Samaha E, Tougeron D, Barbereau D, Caron O, Rahmi G, Barrioz T, Cellier C, Feau S, Lecomte T. Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. Cancers (Basel) 2021;13:1657. [PMID: 33916129 DOI: 10.3390/cancers13071657] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
372 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
373 Xie Y, Shi L, He X, Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf) 2021;9:91-104. [PMID: 34026216 DOI: 10.1093/gastro/goab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
374 Link A, Bornschein J, Thon C. Helicobacter pylori induced gastric carcinogenesis - The best molecular model we have? Best Pract Res Clin Gastroenterol 2021;50-51:101743. [PMID: 33975683 DOI: 10.1016/j.bpg.2021.101743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfartheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis 2021:S1590-8658(21)00100-6. [PMID: 33785282 DOI: 10.1016/j.dld.2021.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist 2021;14:1239-46. [PMID: 33790594 DOI: 10.2147/IDR.S304711] [Reference Citation Analysis]
378 Saito H, Nishikawa Y, Masuzawa Y, Tsubokura M, Mizuno Y. Helicobacter pylori Infection Mass Screening for Children and Adolescents: a Systematic Review of Observational Studies. J Gastrointest Cancer 2021;52:489-97. [PMID: 33761050 DOI: 10.1007/s12029-021-00630-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
379 Charitos IA, D’agostino D, Topi S, Bottalico L. 40 Years of Helicobacter pylori: A Revolution in Biomedical Thought. Gastroenterology Insights 2021;12:111-35. [DOI: 10.3390/gastroent12020011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
380 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
381 Kuo CJ, Lee CH, Chang ML, Lin CY, Lin WR, Su MY, Chiu CH, Tseng CN, Wu YS, Chiu CT, Lai CH. Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect 2021:S1684-1182(21)00059-1. [PMID: 33840604 DOI: 10.1016/j.jmii.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
382 Chiang TH, Chen CC, Tseng PH, Liou JM, Wu MS, Shun CT, Lee YC, Graham DY. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter 2021;26:e12801. [PMID: 33740276 DOI: 10.1111/hel.12801] [Reference Citation Analysis]
383 Leja M, Kortelainen JM, Polaka I, Turppa E, Mitrovics J, Padilla M, Mochalski P, Shuster G, Pohle R, Kashanin D, Klemm R, Ikonen V, Mezmale L, Broza YY, Shani G, Haick H; SniffPhone Project Research Group. Sensing gastric cancer via point-of-care sensor breath analyzer. Cancer 2021;127:1286-92. [PMID: 33739456 DOI: 10.1002/cncr.33437] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
384 Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc 2021:S0929-6646(21)00106-6. [PMID: 33745813 DOI: 10.1016/j.jfma.2021.03.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. United European Gastroenterol J 2021;9:343-53. [PMID: 32962566 DOI: 10.1177/2050640620951403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
387 Yang J, Zhou X, Liu X, Ling Z, Ji F. Role of the Gastric Microbiome in Gastric Cancer: From Carcinogenesis to Treatment. Front Microbiol 2021;12:641322. [PMID: 33790881 DOI: 10.3389/fmicb.2021.641322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
388 Planade O, Dessomme B, Chapelle N, Verdier M, Duchalais E, Queneherve L, Le Rhun M, Coron E, Mosnier JF, Matysiak-Budnik T, Touchefeu Y. Systematic upper endoscopy concomitant with colonoscopy performed within the colorectal cancer screening program: Impact on the patients' management. Clin Res Hepatol Gastroenterol 2021;45:101501. [PMID: 33714864 DOI: 10.1016/j.clinre.2020.07.006] [Reference Citation Analysis]
389 Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol 2021. [PMID: 33691344 DOI: 10.1111/jgh.15468] [Reference Citation Analysis]
390 Spurnic AR, Bukumiric Z, Jevtovic D, Brmbolic B, Pekmezovic T, Salemovic D, Pesic Pavlovic I, Milosevic I, Ranin J, Korac M. Helicobacter pylori infection rates in dyspeptic Serbian HIV-infected patients compared to HIV-negative controls. PLoS One 2021;16:e0248041. [PMID: 33690620 DOI: 10.1371/journal.pone.0248041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Kang SJ, Jung H, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:35-47. [DOI: 10.7704/kjhugr.2020.0056] [Reference Citation Analysis]
392 Yang H, Jung H, Kang SJ, Lee YC, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:59-71. [DOI: 10.7704/kjhugr.2020.0053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the Seroprevalence of Helicobacter pylori among the Lithuanian Medical Students over the Last 25 Years and Its Relation to Dyspeptic Symptoms. Medicina (Kaunas) 2021;57:254. [PMID: 33803389 DOI: 10.3390/medicina57030254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Zullo A, Germanà B, Galliani E, Iori A, de Pretis G, Manfredi G, Buscarini E, Buonocore MR, Monica F. Optimizing the searching for H. pylori in clinical practice with EndoFaster. Dig Liver Dis 2021;53:772-5. [PMID: 33676857 DOI: 10.1016/j.dld.2021.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Zhao JB, Yuan L, Yu XC, Shao QQ, Ma J, Yu M, Wu Y, Qi YB, Hu RB, Wei PR, Jia BL, Zhang LZ, Zhang YR, Ding SZ. Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis. Helicobacter 2021;26:e12793. [PMID: 33675089 DOI: 10.1111/hel.12793] [Reference Citation Analysis]
396 Ji R, Zhao X, Cao X, Zhang Y, Yang Y. Changes in gastric mucosal microbiota in gastric carcinogenesis: a systematic review protocol. BMJ Open 2021;11:e045810. [PMID: 33653765 DOI: 10.1136/bmjopen-2020-045810] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
397 Zhang C, Cao M, Lv T, Wang H, Liu X, Xie Y, Lv N, Chen H, Cram DS, Zhong J, Zhou L. Molecular testing for H. pylori clarithromycin and quinolone resistance: a prospective Chinese study. Eur J Clin Microbiol Infect Dis 2021;40:1599-608. [PMID: 33646449 DOI: 10.1007/s10096-021-04188-4] [Reference Citation Analysis]
398 Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021;21:95. [PMID: 33653284 DOI: 10.1186/s12876-021-01680-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
399 Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Scarpignato C, Hunt RH. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Curr Treat Options Gastro 2021;19:94-132. [DOI: 10.1007/s11938-020-00330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
401 Gholinia N, Shafikhani AA, Hajiaghamohammadi A. Comparing Regimens Based on Clarithromycin, Furazolidone, and Levofloxacin in Patients With Helicobacter Pylori Infection: A Clinical Trial. Int J Enteric Pathog 2021;9:15-20. [DOI: 10.34172/ijep.2021.04] [Reference Citation Analysis]
402 de Korwin JD. [Helicobacter pylori: When to look for an infection and treat it in adults?]. Rev Med Interne 2021;42:482-91. [PMID: 33648778 DOI: 10.1016/j.revmed.2020.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, Kanno T, Sugimoto M, Chiba T, Nomura S, Mieda M, Hiraishi H, Yoshino J, Takagi A, Watanabe S, Koike K. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 2021;56:303-22. [PMID: 33620586 DOI: 10.1007/s00535-021-01769-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 27.0] [Reference Citation Analysis]
404 Yeh JY, Lin HJ, Kuo CJ, Feng CL, Chou CH, Lin CD, Wu HY, Li CY, Chiu CH, Lai CH. Campylobacter jejuni Cytolethal Distending Toxin C Exploits Lipid Rafts to Mitigate Helicobacter pylori-Induced Pathogenesis. Front Cell Dev Biol 2020;8:617419. [PMID: 33708766 DOI: 10.3389/fcell.2020.617419] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
405 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
406 Xie M, Li Q, Zhang B, Zhang Q, Tian QJ, Liu H, Zang YJ, Rao W. Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients. Helicobacter 2021;26:e12791. [PMID: 33600067 DOI: 10.1111/hel.12791] [Reference Citation Analysis]
407 Pellicano R, Ribaldone DG, Caviglia GP. Strategies for Helicobacter pylori eradication in the year 2020. Saudi J Gastroenterol 2020;26:63-5. [PMID: 32295934 DOI: 10.4103/sjg.SJG_95_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
408 Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol 2020;26:78-83. [PMID: 32295932 DOI: 10.4103/sjg.SJG_589_19] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
409 Lee BE, Kim JS, Kim BW, Kim JH, Kim JI, Chung JW, Jeon SW, Lee JH, Kim JH, Kim N, Lee JY, Seo SY, Park SY, Kim SE, Joo MK, Song HJ, Kim KB, Bang CS, Kim HJ. Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years. Helicobacter 2021;26:e12780. [PMID: 33596342 DOI: 10.1111/hel.12780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Bornschein J, Quante M, Jansen M. The complexity of cancer origins at the gastro-oesophageal junction. Best Pract Res Clin Gastroenterol 2021;50-51:101729. [PMID: 33975686 DOI: 10.1016/j.bpg.2021.101729] [Reference Citation Analysis]
411 Leja M, Linē A. Early detection of gastric cancer beyond endoscopy - new methods. Best Pract Res Clin Gastroenterol 2021;50-51:101731. [PMID: 33975677 DOI: 10.1016/j.bpg.2021.101731] [Reference Citation Analysis]
412 Suzuki H, Mori H. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next? United European Gastroenterol J 2021;9:7-8. [PMID: 33210981 DOI: 10.1177/2050640620975357] [Reference Citation Analysis]
413 Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T, Chen Z. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infect Drug Resist 2021;14:535-45. [PMID: 33603417 DOI: 10.2147/IDR.S287631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
414 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
415 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
416 He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. Arab J Gastroenterol 2021;22:47-51. [PMID: 33551347 DOI: 10.1016/j.ajg.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Kaźmierczak-Siedlecka K, Ruszkowski J, Skonieczna-Żydecka K, Jędrzejczak J, Folwarski M, Makarewicz W. Gastrointestinal cancers: the role of microbiota in carcinogenesis and the role of probiotics and microbiota in anti-cancer therapy efficacy. Cent Eur J Immunol 2020;45:476-87. [PMID: 33658894 DOI: 10.5114/ceji.2020.103353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
418 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
419 Hu Y, Ouyang Y, Zhu Y, Lu NH. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Helicobacter 2021;26:e12784. [PMID: 33534148 DOI: 10.1111/hel.12784] [Reference Citation Analysis]
420 Li H, Xia XJ, Zhang LF, Chi JS, Liu P, Wu H, Xie XR, Tian DL, Kun KX, Gong RJ, Liu XM, Xu CX. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. Eur J Gastroenterol Hepatol 2021;32:194-200. [PMID: 32804837 DOI: 10.1097/MEG.0000000000001896] [Reference Citation Analysis]
421 Guo C, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK. Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology 2021;19:314-322.e2. [DOI: 10.1016/j.cgh.2020.03.071] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
422 Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut 2021;70:243-50. [PMID: 32792335 DOI: 10.1136/gutjnl-2020-322200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 20.0] [Reference Citation Analysis]
423 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
424 Mokhtare M, Chaharmahali A, Bahardoust M, Ghanbari A, Sarveazad A, Naghshin R, Abbaskhanidavanloo F. The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial. J Res Med Sci 2021;26:4. [PMID: 34084183 DOI: 10.4103/jrms.JRMS_300_19] [Reference Citation Analysis]
425 Hebel-Gerber S, García-Cancino A, Urbina A, Simirgiotis MJ, Echeverría J, Bustamante-Salazar L, Sáez-Carrillo K, Alarcón J, Pastene-Navarrete E. Chilean Rhubarb, Gunnera tinctoria (Molina) Mirb. (Gunneraceae): UHPLC-ESI-Orbitrap-MS Profiling of Aqueous Extract and its Anti-Helicobacter pylori Activity. Front Pharmacol 2020;11:583961. [PMID: 33708110 DOI: 10.3389/fphar.2020.583961] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
426 Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic Resistance of Helicobacter pylori Strains Isolated From Pediatric Patients in Southwest China. Front Microbiol 2020;11:621791. [PMID: 33574804 DOI: 10.3389/fmicb.2020.621791] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
427 Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
428 Kipritci Z, Gurol Y, Celik G. Antibiotic Resistance Results of Helicobacter pylori in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction. Int J Microbiol 2020;2020:8853298. [PMID: 33488727 DOI: 10.1155/2020/8853298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open 2021;5:307-11. [PMID: 33553672 DOI: 10.1002/jgh3.12492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
430 Li B, Cheung KS, Wong IY, Leung WK, Law S. Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study. Cancer 2021;127:1805-15. [PMID: 33471380 DOI: 10.1002/cncr.33412] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
431 Xue K, Liu Y, Iversen KN, Mazidi M, Qu Z, Dong C, Jin T, Hallmans G, Åman P, Johansson A, He G, Landberg R. Impact of a Fermented High-Fiber Rye Diet on Helicobacter pylori and Cardio-Metabolic Risk Factors: A Randomized Controlled Trial Among Helicobacter pylori-Positive Chinese Adults. Front Nutr 2020;7:608623. [PMID: 33521037 DOI: 10.3389/fnut.2020.608623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
432 Lee JW, Kim N, Nam RH, Yu JE, Son JH, Lee SM, Lee DH. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver 2021;15:53-60. [PMID: 33191308 DOI: 10.5009/gnl20247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
433 Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver 2021;15:3-12. [PMID: 31893631 DOI: 10.5009/gnl19257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
434 Ang TL, Ang D. Helicobacter pylori Treatment Strategies in Singapore. Gut Liver 2021;15:13-8. [PMID: 31875670 DOI: 10.5009/gnl19308] [Reference Citation Analysis]
435 Parreira P, Martins MCL. The biophysics of bacterial infections: Adhesion events in the light of force spectroscopy. Cell Surf 2021;7:100048. [PMID: 33665520 DOI: 10.1016/j.tcsw.2021.100048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Carabotti M, Annibale B, Lahner E. Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach. Nutrients 2021;13:208. [PMID: 33450823 DOI: 10.3390/nu13010208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
437 Rojas García P, van der Pol S, van Asselt ADI, Postma M, Rodríguez-Ibeas R, Juárez-Castelló CA, González M, Antoñanzas F. Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review. Antibiotics (Basel) 2021;10:55. [PMID: 33430005 DOI: 10.3390/antibiotics10010055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
438 Ouyang Y, Liu G, Xu W, Yang Z, Li N, Xie C, Zhou C, Chen J, Zhu Y, Hong J, Lu N. Helicobacter pylori induces epithelial-mesenchymal transition in gastric carcinogenesis via the AKT/GSK3β signaling pathway. Oncol Lett 2021;21:165. [PMID: 33552283 DOI: 10.3892/ol.2021.12426] [Reference Citation Analysis]
439 Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1450-6. [PMID: 33217029 DOI: 10.1111/jgh.15352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021;70:40-54. [PMID: 32958544 DOI: 10.1136/gutjnl-2020-321372] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 46.0] [Reference Citation Analysis]
441 Isaeva G, Isaeva R. Molecular methods for the detection of Helicobacter pylori. Minerva Biotecnol 2020;32. [DOI: 10.23736/s1120-4826.20.02665-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
442 Wärme J, Sundqvist M, Mars K, Aladellie L, Pawelzik SC, Erlinge D, Jernberg T, James S, Hofmann R, Bäck M. Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. Am Heart J 2021;231:105-9. [PMID: 33144087 DOI: 10.1016/j.ahj.2020.10.072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
443 Tóth AG, Csabai I, Maróti G, Jerzsele Á, Dubecz A, Patai ÁV, Judge MF, Nagy SÁ, Makrai L, Bányai K, Szita G, Solymosi N. A glimpse of antimicrobial resistance gene diversity in kefir and yoghurt. Sci Rep 2020;10:22458. [PMID: 33384459 DOI: 10.1038/s41598-020-80444-5] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
444 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
445 Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens 2020;10:15. [PMID: 33379336 DOI: 10.3390/pathogens10010015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
446 Liyen Cartelle A, Uy PP, Koehler TE, Yap JEL. Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice. Cureus 2020;12:e12309. [PMID: 33520508 DOI: 10.7759/cureus.12309] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
447 Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, Huguet JM, Pérez-Lasala J, Molina-Infante J, Barrio J, Fernández-Salazar L, Lanas Á, Perona M, Domínguez-Cajal M, Ortuño J, Gómez-Rodríguez BJ, Almela P, Botargués JM, Núñez Ó, Modolell I, Gómez J, Ruiz-Zorrilla R, De la Coba C, Huerta A, Iyo E, Pozzati L, Antón R, Barenys M, Angueira T, Fernández-Bermejo M, Campillo A, Alcedo J, Pajares-Villaroya R, Mego M, Bermejo F, Dominguez-Jiménez JL, Titó L, Fernández N, Pabón-Carrasco M, Cosme Á, Mata-Romero P, Alcaide N, Ariño I, Di Maira T, Garre A, Puig I, Nyssen OP, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics (Basel) 2020;10:13. [PMID: 33375717 DOI: 10.3390/antibiotics10010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
448 Iqbal U, Khara HS, Akhtar D, Hu Y, Anwar H, Haq KF, Siddiqui HU, Bergenstock MK, Shellenberger MJ. Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterology Res 2020;13:260-8. [PMID: 33447305 DOI: 10.14740/gr1342] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
449 Jukic I, Vukovic J, Rusic D, Bozic J, Bukic J, Leskur D, Seselja Perisin A, Modun D. Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study. Helicobacter 2021;26:e12775. [PMID: 33368852 DOI: 10.1111/hel.12775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
450 Cheng Y, Kou F, Liu J, Dai Y, Li X, Li J. Systematic assessment of environmental factors for gastroesophageal reflux disease: An umbrella review of systematic reviews and meta-analyses. Dig Liver Dis 2021;53:566-73. [PMID: 33339748 DOI: 10.1016/j.dld.2020.11.022] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
451 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
452 Zarzecka U, Matkowska D, Backert S, Skorko-Glonek J. Importance of two PDZ domains for the proteolytic and chaperone activities of Helicobacter pylori serine protease HtrA. Cell Microbiol 2021;23:e13299. [PMID: 33277762 DOI: 10.1111/cmi.13299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
453 Zhang Y, Sun J, Dong Y, Shen X, Zhang Z. Vicenin-2 inhibits the Helicobacterium pylori infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES-1 cells. J Biochem Mol Toxicol 2021;35:e22680. [PMID: 33325628 DOI: 10.1002/jbt.22680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
454 Vörhendi N, Soós A, Anne Engh M, Tinusz B, Szakács Z, Pécsi D, Mikó A, Sarlós P, Hegyi P, Eröss B. Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis.Therap Adv Gastroenterol. 2020;13:1756284820965324. [PMID: 33403002 DOI: 10.1177/1756284820965324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
455 Andreev DN, Maev IV. [Rebamipide: evidence base for use in gastroenterology]. Ter Arkh 2020;92:97-104. [PMID: 33720581 DOI: 10.26442/00403660.2020.12.200455] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
456 Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm. Int J Mol Sci 2020;21:E9507. [PMID: 33327555 DOI: 10.3390/ijms21249507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
457 Sampaio PS, Calado CRC. Potential of FTIR-Spectroscopy for Drugs Screening against Helicobacter pylori. Antibiotics (Basel) 2020;9:E897. [PMID: 33322665 DOI: 10.3390/antibiotics9120897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
458 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261-87. [DOI: 10.7704/kjhugr.2020.0045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
459 Gladyshev N, Taame M, Kravtsov V. Clinical and laboratory importance of detecting Helicobacter pylori coccoid forms for the selection of treatment. Prz Gastroenterol 2020;15:294-300. [PMID: 33777268 DOI: 10.5114/pg.2020.101557] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
460 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
461 Otani K, Watanabe T, Kosaka S, Matsumoto Y, Nakata A, Nadatani Y, Fukunaga S, Hosomi S, Tanaka F, Kamata N, Taira K, Nagami Y, Tanigawa T, Kimura T, Fukumoto S, Kawada N, Fujiwara Y. Utility of Kyoto Classification of Gastritis in subjects with a high-negative titer of anti-Helicobacter pylori antibody during a medical check-up. J Clin Biochem Nutr 2020;67:317-22. [PMID: 33293774 DOI: 10.3164/jcbn.20-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
462 Marques AT, Vítor JMB, Santos A, Oleastro M, Vale FF. Trends in Helicobacter pylori resistance to clarithromycin: from phenotypic to genomic approaches. Microb Genom 2020;6. [PMID: 32118532 DOI: 10.1099/mgen.0.000344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
463 Tang B, Tang L, Huang C, Tian C, Chen L, He Z, Yang G, Zuo L, Zhao G, Liu E, Wang S, Lin H, He J, Yang S. The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial.Infect Dis Ther. 2021;10:317-333. [PMID: 33270205 DOI: 10.1007/s40121-020-00372-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
464 Chang S, Shih Y, Lee W, Kuo M, Tsay F, Kuo L, Huang W, Shie C. 14‐day reverse hybrid therapy vs 7‐day concomitant therapy in the first‐line treatment of Helicobacter pylori infection. Adv in Digestive Medicine 2022;9:38-43. [DOI: 10.1002/aid2.13243] [Reference Citation Analysis]
465 Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021;85:1-13. [PMID: 33279389 DOI: 10.1016/j.ejim.2020.11.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
466 Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020;69:2093-112. [PMID: 33004546 DOI: 10.1136/gutjnl-2020-322368] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 35.0] [Reference Citation Analysis]
467 Boyanova L, Hadzhiyski P. Helicobacter pylori infection is associated with anemia, weight loss or both conditions among Bulgarian children. Acta Microbiol Immunol Hung 2020;67:239-42. [PMID: 33258794 DOI: 10.1556/030.2020.01158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Zullo A. The current role of dual therapy for treatment of Helicobacter pylori: back to the future? Eur J Gastroenterol Hepatol 2020;32:555-6. [PMID: 31922977 DOI: 10.1097/MEG.0000000000001654] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
469 Alavifard H, Mirzaei N, Yadegar A, Baghaei K, Smith SM, Sadeghi A, Zali MR. Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study. Curr Microbiol 2021;78:244-54. [PMID: 33251569 DOI: 10.1007/s00284-020-02295-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
470 Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, Dallio M, Federico A, Romano M. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med 2020;9:E3887. [PMID: 33265933 DOI: 10.3390/jcm9123887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
471 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
472 Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, Yatagai N, Akazawa Y, Ueda K, Ueyama H, Nagahara A. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol 2020;13:1756284820966247. [PMID: 33240391 DOI: 10.1177/1756284820966247] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
473 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
474 Adriani A, Saracco GM, Pellicano R. Helicobacter pylori infection and dermatologic diseases: time to turn the page? G Ital Dermatol Venereol 2020;155:709-10. [PMID: 33228342 DOI: 10.23736/S0392-0488.20.06855-8] [Reference Citation Analysis]
475 Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol 2020;10:572912. [PMID: 33330122 DOI: 10.3389/fcimb.2020.572912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 65] [Article Influence: 3.0] [Reference Citation Analysis]
476 Piazuelo MB, Bravo LE, Mera RM, Camargo MC, Bravo JC, Delgado AG, Washington MK, Rosero A, Garcia LS, Realpe JL, Cifuentes SP, Morgan DR, Peek RM Jr, Correa P, Wilson KT. The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions. Gastroenterology 2021;160:1106-1117.e3. [PMID: 33220252 DOI: 10.1053/j.gastro.2020.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
477 Wu D, Sun Z, Li T, Tan Q, Sun Y, Chen T, Liu Y, Li J, Jiang H, Yuan Z, Zhao Y, Chen W. Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial. BMJ Open 2020;10:e037182. [PMID: 33203625 DOI: 10.1136/bmjopen-2020-037182] [Reference Citation Analysis]
478 Han ML, Liou JM, Ser KH, Chen JC, Chen SC, Lee WJ. Changes of serum pepsinogen level and ABC classification after bariatric surgery. J Formos Med Assoc 2021;120:1377-85. [PMID: 33199102 DOI: 10.1016/j.jfma.2020.10.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
479 Chapelle N, Jirka I, Péron M, Quénéhervé L, Cauchin E, Touchefeu Y, Coron E, Mosnier JF, Matysiak-Budnik T. Evaluation of a Phone Call Reminder Strategy in the Surveillance of Patients with Gastric Precancerous Lesions Lost to Follow-Up. Gastrointest Tumors 2020;7:110-6. [PMID: 33173774 DOI: 10.1159/000508873] [Reference Citation Analysis]
480 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
481 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
482 Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol 2020;11:549084. [PMID: 33281754 DOI: 10.3389/fmicb.2020.549084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
483 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
484 Zhang J, Guo J, Li D, Chen M, Liu J, Feng C, He Q, Zhao J, Zhang L, Chen J, Shi Y. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. Medicine (Baltimore) 2020;99:e22976. [PMID: 33157939 DOI: 10.1097/MD.0000000000022976] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
485 Kim YI, Kim YA, Lee JW, Kim HJ, Kim SH, Kim SG, Kim JI, Kim JJ, Choi IJ. Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension. Gut Liver. 2020;14:47-56. [PMID: 30974928 DOI: 10.5009/gnl18510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
486 Willems P, de Repentigny J, Hassan GM, Sidani S, Soucy G, Bouin M. The Prevalence of Helicobacter pylori Infection in a Quaternary Hospital in Canada. J Clin Med Res 2020;12:687-92. [PMID: 33224369 DOI: 10.14740/jocmr4348] [Reference Citation Analysis]
487 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
488 Zhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. Intelligence-Based Medicine 2020;1-2:100004. [DOI: 10.1016/j.ibmed.2020.100004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
489 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
490 Miqueleiz-zapatero A, Alba-rubio C, Domingo-garcía D, Cantón R, Gómez-garcía de la Pedrosa E, Aznar-cano E, Leiva J, Montes M, Sánchez-romero I, Rodríguez-díaz JC, Alarcón-cavero T. First national survey on the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain. Enfermedades infecciosas y microbiologia clinica (English ed ) 2020;38:410-6. [DOI: 10.1016/j.eimce.2019.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
491 Llorca-otero L, Toro-rueda C. Diagnosis of Helicobacter pylori infection: Progress and challenges. Enfermedades Infecciosas y Microbiología Clínica 2020;38:407-9. [DOI: 10.1016/j.eimc.2020.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
492 Huang T, Yang S, Tai W, Liang C, Kuo C, Yao C, Wu C, Kuo Y, Chou Y, Lee C, Wu K, Chuah S. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomedical Journal 2020. [DOI: 10.1016/j.bj.2020.11.012] [Reference Citation Analysis]
493 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy. J Clin Gastroenterol 2021;55:865-8. [PMID: 33136782 DOI: 10.1097/MCG.0000000000001457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
494 Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1392-402. [PMID: 33037845 DOI: 10.1111/jgh.15294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
495 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Reference Citation Analysis]
496 Arj A, Mollaei M, Razavizadeh M, Moraveji A. The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication. J Res Pharm Pract 2020;9:101-5. [PMID: 33102384 DOI: 10.4103/jrpp.JRPP_19_86] [Reference Citation Analysis]
497 Zhou A, Li L, Zhao G, Min L, Liu S, Zhu S, Guo Q, Liu C, Zhang S, Li P. Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice. Front Cell Infect Microbiol 2020;10:566730. [PMID: 33194806 DOI: 10.3389/fcimb.2020.566730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
498 Glover B, Teare J, Ashrafian H, Patel N. The endoscopic predictors of Helicobacter pylori status: a meta-analysis of diagnostic performance. Ther Adv Gastrointest Endosc 2020;13:2631774520950840. [PMID: 33150333 DOI: 10.1177/2631774520950840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
499 Mégraud F, Alix C, Charron P, Bénéjat L, Ducournau A, Bessède E, Lehours P. Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter 2021;26:e12767. [PMID: 33090614 DOI: 10.1111/hel.12767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
500 Ke H, Li J, Lu B, Yang C, Wang J, Wang Z, Liu L, Chen Y. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter 2021;26:e12768. [PMID: 33089598 DOI: 10.1111/hel.12768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
501 Li L, Jing J, Gao H, Zhang C, Lou H, Pan W. Regular arrangement of collecting venules under endoscopy for predicting a Helicobacter pylori-negative stomach: A systematic review and meta-analysis. Gastroenterol Hepatol 2021;44:286-92. [PMID: 33097281 DOI: 10.1016/j.gastrohep.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
502 Losurdo G, Giorgio F, Pricci M, Girardi B, Russo F, Riezzo G, Martulli M, Piazzolla M, Cocomazzi F, Abbruzzi F, Parente E, Paolillo R, Mileti A, Iannone A, Principi M, Ierardi E, Leo AD. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics (Basel) 2020;9:E723. [PMID: 33096925 DOI: 10.3390/antibiotics9100723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
503 Bilgilier C, Thannesberger J, Ojeda Cisneros M, Boehnke K, Wu J, Xi C, Bussalleu Rivera A, Steininger C. Antimicrobial Resistance of Helicobacter pylori in Gastric Biopsy Samples from Lima/Peru. Microb Drug Resist 2021;27:951-5. [PMID: 33085931 DOI: 10.1089/mdr.2020.0241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
504 Hofreuter D, Behrendt J, Franz A, Meyer J, Jansen A, Bluemel B, Eisele B, Koken M, Glocker EO. Antimicrobial resistance of Helicobacter pylori in an eastern German region. Helicobacter 2021;26:e12765. [PMID: 33067911 DOI: 10.1111/hel.12765] [Reference Citation Analysis]
505 Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635-648. [PMID: 32861308 DOI: 10.1016/s0140-6736(20)31288-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 81.0] [Reference Citation Analysis]
506 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
507 Suceveanu AI, Suceveanu AP, Parepa I, Mazilu L, Pantea-Stoian A, Diaconu C, Botea F, Herlea V, Micu SI, Tuta LA, Costea DO, Voinea F. Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with Helicobacter pylori. Exp Ther Med 2020;20:205. [PMID: 33123234 DOI: 10.3892/etm.2020.9335] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
508 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Intest Res 2021;19:127-57. [PMID: 33045799 DOI: 10.5217/ir.2020.00020] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
509 Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 2020;9:E3253. [PMID: 33053671 DOI: 10.3390/jcm9103253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
510 Zhang W, Lian Y, Li Q, Sun L, Chen R, Lai X, Lai Z, Yuan E, Sun S. Preventative and Therapeutic Potential of Flavonoids in Peptic Ulcers. Molecules 2020;25:E4626. [PMID: 33050668 DOI: 10.3390/molecules25204626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
511 Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel) 2020;9:E685. [PMID: 33050205 DOI: 10.3390/antibiotics9100685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
512 Sato Y, Sato T, Matsushima J, Fujii A, Ono Y, Suda T, Katayama Y, Ban S. Histopathologic Change of a Case of Gastric Oxyntic Neoplasm (Gastric Adenocarcinoma of Fundic Gland Mucosa Type) Through 5 Years With Concurrent Other Oxyntic Gland Lesions. Int J Surg Pathol 2021;29:557-64. [PMID: 33030084 DOI: 10.1177/1066896920962574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
513 Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. Microbiologyopen 2020;9:e1120. [PMID: 33026166 DOI: 10.1002/mbo3.1120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
514 Lee SW, Moon SJ, Kim SH, Jung SH, Song KH, Kim SM, Sung JK, Lee DS. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine (Baltimore) 2020;99:e22137. [PMID: 32957336 DOI: 10.1097/MD.0000000000022137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
515 Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
516 Bornschein J, Tran-Nguyen T, Fernandez-Esparrach G, Ash S, Balaguer F, Bird-Lieberman EL, Córdova H, Dzerve Z, Fassan M, Leja M, Lyutakov I, Middelburg T, Moreira L, Nakov R, Nieuwenburg SAV, O'Connor A, Realdon S, De Schepper H, Smet A, Spaander MCW, Tolmanis I, Urbonas T, Weigt J, Hold GL, Link A, Kupcinskas J; ENIGMA: European Network for the Investigation of Gastrointestinal Mucosal Alterations. Biopsy Sampling in Upper Gastrointestinal Endoscopy: A Survey from 10 Tertiary Referral Centres Across Europe. Dig Dis 2021;39:179-89. [PMID: 33002891 DOI: 10.1159/000511867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
517 Marcos P, Brito-Gonçalves G, Libânio D, Pita I, Castro R, Sá I, Dinis-Ribeiro M, Pimentel-Nunes P. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut 2020;69:1762-8. [PMID: 32051208 DOI: 10.1136/gutjnl-2019-320091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
518 Bornschein J, Rugge M. Bright future for endoscopy: the new frontier of gastric cancer secondary prevention. Gut 2020;69:1723-4. [PMID: 32532892 DOI: 10.1136/gutjnl-2020-321570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
519 Wands DIF, El-Omar EM, Hansen R. Helicobacter pylori: getting to grips with the guidance. Frontline Gastroenterol 2021;12:650-5. [PMID: 34917323 DOI: 10.1136/flgastro-2020-101571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
521 Kim JL, Kim SG, Lee A, Choi J, Chung H, Cho SJ. Long-term natural history after endoscopic resection for gastric dysplasia. Surg Endosc 2021;35:5247-55. [PMID: 32989550 DOI: 10.1007/s00464-020-08023-3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
522 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
523 Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol 2020;115:1226-35. [PMID: 32221162 DOI: 10.14309/ajg.0000000000000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
524 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
525 Wang YH, Wang FF, Gong XL, Yan LL, Zhao QY, Song YP, Zhao RL, He YJ, Zhou L, Liu DS, Xie Y. Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance. Therap Adv Gastroenterol 2020;13:1756284820952596. [PMID: 33029198 DOI: 10.1177/1756284820952596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
526 Nestegard O, Johnsen KM, Sørbye SW, Halvorsen FA, Tønnessen T, Paulssen EJ, Melby KK, Goll R, Florholmen J. Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication. PLoS One 2020;15:e0238944. [PMID: 32966303 DOI: 10.1371/journal.pone.0238944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
527 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
528 A Castaneda C, Castillo M, Sanchez J, Casavilca S, Sanchez J, A Bernabe L, Suarez N, Chavez I, Ruiz E, Tello K, R Villa M, Zevallos R, Montenegro P, Dias-Neto E, Landa-Baella M, Taxa L. Detection of Helicobacter pylori in gastric cancer tissue through histopathology, immunohistochemistry and real-time reverse transcription-PCR. Future Microbiol 2020;15:1131-7. [PMID: 32954850 DOI: 10.2217/fmb-2019-0280] [Reference Citation Analysis]
529 Zheng W, Zhang X, Kim JJ, Zhu X, Ye G, Ye B, Wang J, Luo S, Li J, Yu T, Liu J, Hu W, Si J. High Accuracy of Convolutional Neural Network for Evaluation of Helicobacter pylori Infection Based on Endoscopic Images: Preliminary Experience. Clin Transl Gastroenterol. 2019;10:e00109. [PMID: 31833862 DOI: 10.14309/ctg.0000000000000109] [Cited by in Crossref: 22] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
530 Sugimoto M, Murata M, Mizuno H, Iwata E, Nagata N, Itoi T, Kawai T. Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis. J Clin Med 2020;9:E3007. [PMID: 32961949 DOI: 10.3390/jcm9093007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
531 Romstad KK, Detlie TE, Søberg T, Ricanek P, Jahnsen ME, Lerang F, Jahnsen J. Gastrointestinal bleeding due to peptic ulcers and erosions – a prospective observational study (BLUE study). Scandinavian Journal of Gastroenterology 2020;55:1139-45. [DOI: 10.1080/00365521.2020.1819405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
532 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
533 Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol 2020;55:1054-61. [PMID: 32930864 DOI: 10.1007/s00535-020-01723-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
534 Lee GH, Lee KM, Shin SJ, Kang JK, Noh CK, Kim JH, Lim SG. Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection. Korean J Intern Med 2020;35:1094-103. [PMID: 32921010 DOI: 10.3904/kjim.2020.174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
535 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
536 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Steinbuss G, Kriegsmann K, Kriegsmann M. Identification of Gastritis Subtypes by Convolutional Neuronal Networks on Histological Images of Antrum and Corpus Biopsies. Int J Mol Sci. 2020;21. [PMID: 32932860 DOI: 10.3390/ijms21186652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
538 Vlăduţ C, Ciocîrlan M, Costache RS, Jinga M, Balaban VD, Costache DO, Diculescu M. Is mucosa-associated lymphoid tissue lymphoma an infectious disease? Role of Helicobacter pylori and eradication antibiotic therapy (Review). Exp Ther Med 2020;20:3546-53. [PMID: 32905014 DOI: 10.3892/etm.2020.9031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
539 Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
540 Tang X, Chen X, Shen Y, Yang T, Hu R, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population. Future Microbiol 2020;15:1353-61. [PMID: 32900223 DOI: 10.2217/fmb-2020-0206] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
541 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
542 Toh JWT, Wilson RB. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci 2020;21:E6451. [PMID: 32899442 DOI: 10.3390/ijms21176451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
543 Maev IV, Andreev DN, Govorun VM, Ilina EN, Kucheryavyy YA, Oganesian TS, Melnikova EV, Zayratyants OV, Parfenova TV, Dzhedzheia LV, Kirillova NV, Maevskaya EA, Fomenko AK, Lobanova EG, Zaborovskii AV, Kriukov KA. [Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]. Ter Arkh 2020;92:24-8. [PMID: 33346458 DOI: 10.26442/00403660.2020.08.000761] [Reference Citation Analysis]
544 Abdulkhakov SR, Bordin DS, Abdulkhakov RA, Safina DD, Gizdatullina AR, Gimadieva LZ, Safina GM, Ziyatdinov AI, Maturina AM, Nyssen OP, Megraud F, O'Morain C, Perez-Gisbert J. [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. Ter Arkh 2020;92:52-9. [PMID: 33346462 DOI: 10.26442/00403660.2020.08.000758] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
545 Costa L, Corre S, Michel V, Le Luel K, Fernandes J, Ziveri J, Jouvion G, Danckaert A, Mouchet N, Da Silva Barreira D, Torres J, Camorlinga M, D'Elios MM, Fiette L, De Reuse H, Galibert MD, Touati E. USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis. Gut 2020;69:1582-91. [PMID: 31822580 DOI: 10.1136/gutjnl-2019-318640] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
546 Mathews J, Malik P, Rai A, Lin J, Kim RS, Pan DH. A single centre experience of treatment outcomes for Helicobacter pylori infection among inner-city children and adolescents. Acta Paediatr 2020;109:1860-6. [PMID: 31880339 DOI: 10.1111/apa.15150] [Reference Citation Analysis]
547 Teng G, Liu Y, Wu T, Wang W, Wang H, Hu F. Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by Helicobacter pylori and Its Effect on Gastrointestinal Flora. Biomed Res Int 2020;2020:4936318. [PMID: 32934960 DOI: 10.1155/2020/4936318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
548 Pichon M, Tran CT, Motillon G, Debiais C, Gautier S, Aballea M, Cremniter J, Vasseur P, Tougeron D, Garcia M, Garnier M, Bodet C, Faure JP, Burucoa C. Where to Biopsy to Detect Helicobacter pylori and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach. J Clin Med 2020;9:E2812. [PMID: 32878081 DOI: 10.3390/jcm9092812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
549 Kong S, Huang K, Wang J, Wang X, Yang N, Dong Y, Zhuang Y, Dang Y, Zhang G, Ye F. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathog 2020;12:39. [PMID: 32874206 DOI: 10.1186/s13099-020-00378-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
550 da Silva FAF, de Brito BB, Santos MLC, Marques HS, Sampaio MM, da Silva Júnior RT, Apolonio JS, de Carvalho LS, Silva CS, de Sá Santos LK, Oliveira MV, Rocha GA, de Magalhães Queiroz DM, de Melo FF. Treatment of Helicobacter pylori infection in children: A systematic review. World J Meta-Anal 2020; 8(4): 292-308 [DOI: 10.13105/wjma.v8.i4.292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
552 Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi C. Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Helicobacter pylori Infected Patients: A Retrospective Study. Antibiotics (Basel) 2020;9:E549. [PMID: 32872117 DOI: 10.3390/antibiotics9090549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
553 Aguilera Matos I, Diaz Oliva SE, Escobedo AA, Villa Jiménez OM, Velazco Villaurrutia YDC. Helicobacter pylori infection in children. BMJ Paediatr Open 2020;4:e000679. [PMID: 32818155 DOI: 10.1136/bmjpo-2020-000679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
554 Chiang TH, Chiu SY, Chen SL, Yen AM, Fann JC, Liu CY, Chou CK, Chiu HM, Shun CT, Wu MS, Lin JT, Lee YC, Chen TH, Lin MW. Serum Pepsinogen as a Predictor for Gastric Cancer Death: A 16-Year Community-based Cohort Study. J Clin Gastroenterol. 2019;53:e186-e193. [PMID: 29369241 DOI: 10.1097/mcg.0000000000000992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
555 Zhao Y, Ren M, Wang X, Lu G, Lu X, Zhang D, He S. Telephone-Based Reeducation of Drug Administration for Helicobacterpylori Eradication: A Multicenter Randomized Controlled Study. Gastroenterol Res Pract 2020;2020:8972473. [PMID: 32802048 DOI: 10.1155/2020/8972473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
556 Zhang L, Liu J, Meng F, Guan Y, Wang Y, Zhu S, Liu Y, Xie Q, Yu J, Zhang S. Pharmacokinetics of Bismuth following Oral Administration of Wei Bi Mei in Healthy Chinese Volunteers. Evid Based Complement Alternat Med 2020;2020:2679034. [PMID: 32855646 DOI: 10.1155/2020/2679034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
557 Duda-Madej A, Kozłowska J, Krzyżek P, Anioł M, Seniuk A, Jermakow K, Dworniczek E. Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria. Molecules 2020;25:E3642. [PMID: 32785151 DOI: 10.3390/molecules25163642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
558 Jeong SJ, Lee KH, Kim JH, Park SY, Song YG. Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model. Antibiotics (Basel) 2020;9:E502. [PMID: 32785101 DOI: 10.3390/antibiotics9080502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
559 Gudra D, Pupola D, Skenders G, Leja M, Radovica-Spalvina I, Gorskis H, Vangravs R, Fridmanis D. Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event. Helicobacter 2020;25:e12748. [PMID: 32776403 DOI: 10.1111/hel.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
560 Lok CH, Zhu D, Wang J, Ren YT, Jiang X, Li SJ, Zhao XY. Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing. Infect Drug Resist 2020;13:2145-53. [PMID: 32753910 DOI: 10.2147/IDR.S249370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
561 Gasenko E, Leja M, Polaka I, Hegmane A, Murillo R, Bordin D, Link A, Kulju M, Mochalski P, Shani G, Malfertheiner P, Herrero R, Haick H. How do international gastric cancer prevention guidelines influence clinical practice globally? Eur J Cancer Prev 2020;29:400-7. [PMID: 32740165 DOI: 10.1097/CEJ.0000000000000580] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
562 Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020;15:1185-96. [PMID: 32954842 DOI: 10.2217/fmb-2020-0084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
563 Chen CC, Luo JC, Fang YJ, Lee JY, Kuo CC, Yang TH, Chiu MC, Yu JJ, Bair MJ, Chen PY, Chou CK, Chen CY, Chang CY, Hsu YC, Tseng CH, Hsu WF, Hu WH, Tsai MH, Hsieh CL, Chen MJ, Shun CT, Liu TY, Lee YC, Liou JM, Wu MS; and for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial. Therap Adv Gastroenterol 2020;13:1756284820927306. [PMID: 32821287 DOI: 10.1177/1756284820927306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
564 Toyoshima O, Nishizawa T, Sekiba K, Matsuno T, Kondo R, Watanabe H, Suzuki H, Tanikawa C, Koike K, Matsuda K. A single nucleotide polymorphism in Prostate Stem Cell Antigen is associated with endoscopic grading in Kyoto classification of gastritis. J Clin Biochem Nutr. 2020;. [PMID: 33536715 DOI: 10.3164/jcbn.20-67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
565 Santos MLC, de Brito BB, da Silva FAF, Sampaio MM, Marques HS, Oliveira e Silva N, de Magalhães Queiroz DM, de Melo FF. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol 2020; 26(28): 4076-4093 [PMID: 32821071 DOI: 10.3748/wjg.v26.i28.4076] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
566 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
567 Sholeh M, Maleki F, Krutova M, Bavari S, Golmoradi R, Sadeghifard N, Amiriani T, Kouhsari E. The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis. Helicobacter 2020;25:e12730. [PMID: 32705749 DOI: 10.1111/hel.12730] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
568 Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YAA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S, Yamaoka Y. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel) 2020;12:E473. [PMID: 32722296 DOI: 10.3390/toxins12080473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
569 Chen Z, Chen H, Yu L, Xin H, Kong J, Bai Y, Zeng W, Zhang J, Wu Q, Fan H. Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection. J Cell Physiol 2021;236:1158-83. [PMID: 32710499 DOI: 10.1002/jcp.29925] [Reference Citation Analysis]
570 Chapelle N, Petryszyn P, Blin J, Leroy M, Le Berre-Scoul C, Jirka I, Neunlist M, Moussata D, Lamarque D, Olivier R, Tougeron D, Mosnier JF, Matysiak-Budnik T. A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. Helicobacter 2020;25:e12727. [PMID: 32700438 DOI: 10.1111/hel.12727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
571 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
572 Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med 2021;112:281-7. [PMID: 32700868 DOI: 10.23736/S0026-4806.20.06810-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
573 Xiong X, Chen J, He M, Wu T, Yang H. Helicobacter pylori infection and the prevalence of hypertension in Chinese adults: The Dongfeng-Tongji cohort. J Clin Hypertens (Greenwich) 2020;22:1389-95. [PMID: 32687255 DOI: 10.1111/jch.13928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
574 Khiddi F, Abdellahi MVM, Horma MA, Billoet A, Collobert G, Amar AM, Nech HDM, Vadel EHM, Houmeida A, Raymond J, Dauga C, Gastli N. Characteristics of Helicobacter pylori strains isolated from Mauritanian patients. Helicobacter 2020;25:e12726. [PMID: 32686319 DOI: 10.1111/hel.12726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Corojan AL, Dumitrașcu DL, Ciobanca P, Leucuta DC. Prevalence of Helicobacter pylori infection among dyspeptic patients in Northwestern Romania: A decreasing epidemiological trend in the last 30 years. Exp Ther Med 2020;20:3488-92. [PMID: 32905167 DOI: 10.3892/etm.2020.9024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
576 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
577 Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
578 Panarese A, Galatola G, Armentano R, Pimentel-Nunes P, Ierardi E, Caruso ML, Pesce F, Lenti MV, Palmitessa V, Coletta S, Shahini E. Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions. World J Gastroenterol 2020; 26(26): 3834-3850 [PMID: 32774061 DOI: 10.3748/wjg.v26.i26.3834] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
579 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
580 Han Y, Dai W, Meng F, Gan X, Liu M, Deng X, Li Y, Wang G. Diagnosis of Helicobacter pylori infection in the elderly using an immunochromatographic assay-based stool antigen test. Microbiologyopen 2020;9:e1102. [PMID: 32666705 DOI: 10.1002/mbo3.1102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
581 Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. J Chemother 2020;32:273-85. [PMID: 32657237 DOI: 10.1080/1120009X.2020.1790889] [Reference Citation Analysis]
582 Fiori-Duarte AT, Rodrigues RP, Kitagawa RR, Kawano DF. Insights into the Design of Inhibitors of the Urease Enzyme - A Major Target for the Treatment of Helicobacter pylori Infections. Curr Med Chem 2020;27:3967-82. [PMID: 30827224 DOI: 10.2174/0929867326666190301143549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
583 Palamides P, Jolaiya T, Idowu A, Loell E, Onyekwere C, Ugiagbe R, Agbo I, Lesi O, Ndububa D, Adekanle O, Carranza M, Ally R, Njom H, Adeleye IA, Harrison U, Clarke A, Fischer W, Smith S, Haas R. Helicobacter pylori patient isolates from South Africa and Nigeria differ in virulence factor pathogenicity profile and associated gastric disease outcome. Sci Rep 2020;10:11409. [PMID: 32651394 DOI: 10.1038/s41598-020-66128-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
584 Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
585 Crafa P, Franceschi M, Rodriguez Castro KI, Barchi A, Russo M, Franzoni L, Antico A, Baldassarre G, Panozzo MP, Di Mario F. Functional Dyspesia. Acta Biomed 2020;91:e2020069. [PMID: 32921764 DOI: 10.23750/abm.v91i3.10150] [Reference Citation Analysis]
586 de Almeida NM, Fernandes A, Romãozinho JM, Freire P, Donato MM, Cardoso O, Luxo C, Cipriano MA, Marinho C, Calhau C, Figueiredo P. Correlation of NOD2 genotypes with Helicobacter pylori infection in a South‐European country. Adv in Digestive Med 2021;8:163-71. [DOI: 10.1002/aid2.13210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
587 Tucker RM, Augustin AD, Hayee BH, Bjarnason I, Taylor D, Weller C, Charlett A, Dobbs SM, Dobbs RJ. Role of Helicobacters in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism. J Clin Med 2020;9:E2159. [PMID: 32650535 DOI: 10.3390/jcm9072159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
588 Zizzi CF, Pellicano R, Biancone L. The relationship between Helicobacter pylori and chronic kidney disease: update 2020. Minerva Gastroenterol Dietol 2020;66:343-9. [PMID: 32623870 DOI: 10.23736/S1121-421X.20.02729-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
589 Yuan L, Zhao JB, Zhou YL, Qi YB, Guo QY, Zhang HH, Khan MN, Lan L, Jia CH, Zhang YR, Ding SZ. Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area. World J Gastroenterol 2020; 26(25): 3673-3685 [PMID: 32742135 DOI: 10.3748/wjg.v26.i25.3673] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
590 Bosch DE, Krumm N, Wener MH, Yeh MM, Truong CD, Reddi DM, Liu Y, Swanson PE, Schmidt RA, Bryan A. Serology Is More Sensitive Than Urea Breath Test or Stool Antigen for the Initial Diagnosis of Helicobacter pylori Gastritis When Compared With Histopathology. Am J Clin Pathol 2020;154:255-65. [PMID: 32445464 DOI: 10.1093/ajcp/aqaa043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
591 Bari Z, Fakheri H, Taghvaei T, Yaghoobi M. A Comparison between 10-day and 12-day Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2020;12:106-10. [PMID: 32626563 DOI: 10.34172/mejdd.2020.169] [Reference Citation Analysis]
592 Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020;7:CD005583. [PMID: 32628791 DOI: 10.1002/14651858.CD005583.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
593 Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, Yang Y, Zhang D. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. European Journal of Gastroenterology & Hepatology 2021;33:775-86. [DOI: 10.1097/meg.0000000000001835] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
594 Mosso E, Bonetto S, Longobardi G, Abenavoli L, Ribaldone DG, Saracco GM, Pellicano R. Management of functional dyspepsia in 2020: a clinical point of view. Minerva Gastroenterol Dietol 2020;66:331-42. [PMID: 32623872 DOI: 10.23736/S1121-421X.20.02732-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
595 Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single‐arm study. Helicobacter 2020;25. [DOI: 10.1111/hel.12719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
596 Hsieh MT, Chang WL, Wu CT, Yang HB, Kuo HY, Lin MY, Cheng HC, Tsai YC, Sheu BS. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen. Eur J Clin Pharmacol 2020;76:1581-9. [PMID: 32591943 DOI: 10.1007/s00228-020-02938-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
597 Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. J Antimicrob Chemother 2019;74:1069-77. [PMID: 30668729 DOI: 10.1093/jac/dky510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
598 Gökışık MT, Uyar S. The role of Helicobacter pylori in vitamin-B12 deficiency due to metformin use. Helicobacter 2020;25:e12718. [PMID: 32559822 DOI: 10.1111/hel.12718] [Reference Citation Analysis]
599 Gong EJ, Ahn JY, Kim JM, Lee SM, Na HK, Lee JH, Jung KW, Choi KD, Kim DH, Song HJ, Lee GH, Kim SW, Jung HY. Genotypic and Phenotypic Resistance to Clarithromycin in Helicobacter pylori Strains. J Clin Med 2020;9:E1930. [PMID: 32575584 DOI: 10.3390/jcm9061930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
600 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
601 Lahner E, Conti L, Annibale B, Corleto VD. Current Perspectives in Atrophic Gastritis. Curr Gastroenterol Rep 2020;22:38. [PMID: 32542467 DOI: 10.1007/s11894-020-00775-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
602 Doulberis M, Papaefthymiou A, Polyzos SA, Bargiotas P, Liatsos C, Srivastava DS, Zavos C, Katsinelos P, Kountouras J. Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. Microorganisms 2020;8:E894. [PMID: 32545826 DOI: 10.3390/microorganisms8060894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
603 Na'amnih W, Ben Tov A, Bdair-Amsha A, Cohen S, Tsamir J, Chodick G, Muhsen K. Physicians' adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study. Isr J Health Policy Res 2020;9:28. [PMID: 32527326 DOI: 10.1186/s13584-020-00389-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
604 Tshibangu-Kabamba E, Ngoma-Kisoko PJ, Tuan VP, Matsumoto T, Akada J, Kido Y, Tshimpi-Wola A, Tshiamala-Kashala P, Ahuka-Mundeke S, Ngoy DM, Disashi-Tumba G, Yamaoka Y. Next-Generation Sequencing of the Whole Bacterial Genome for Tracking Molecular Insight into the Broad-Spectrum Antimicrobial Resistance of Helicobacter pylori Clinical Isolates from the Democratic Republic of Congo. Microorganisms 2020;8:E887. [PMID: 32545318 DOI: 10.3390/microorganisms8060887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
605 Park CH, Yang D, Kim JW, Kim J, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak M, Kim B, Lee HJ, Lee HS, Choi M, Park D, Lee JY, Byeon J, Park CG, Cho JY, Lee ST, Chun HJ. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer. Korean J Helicobacter Up Gastrointest Res 2020;20:117-45. [DOI: 10.7704/kjhugr.2020.0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
606 Bénéjat L, Buissonnière A, Ducournau A, Mégraud F, Bessède E, Lehours P. Evaluation of RIDASCREEN® and RIDA®QUICK Helicobacter kits for Helicobacter pylori detection in stools. Eur J Clin Microbiol Infect Dis 2020;39:1941-3. [PMID: 32519216 DOI: 10.1007/s10096-020-03943-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
607 Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS;  Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19:1109-1120. [PMID: 31559966 DOI: 10.1016/s1473-3099(19)30272-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 67] [Article Influence: 21.5] [Reference Citation Analysis]
608 Ye Q, Shao X, Shen R, Chen D, Shen J. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Helicobacter 2020;25:e12713. [PMID: 32515529 DOI: 10.1111/hel.12713] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
609 Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis 2020;52:862-8. [PMID: 32505566 DOI: 10.1016/j.dld.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
610 Sharara AI. Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities. Clin Gastroenterol Hepatol 2021;19:232-4. [PMID: 32492481 DOI: 10.1016/j.cgh.2020.05.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
611 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
612 Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 2020;69:1019-26. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 27.0] [Reference Citation Analysis]
613 Bockerstett KA, Lewis SA, Wolf KJ, Noto CN, Jackson NM, Ford EL, Ahn TH, DiPaolo RJ. Single-cell transcriptional analyses of spasmolytic polypeptide-expressing metaplasia arising from acute drug injury and chronic inflammation in the stomach. Gut 2020;69:1027-38. [PMID: 31481545 DOI: 10.1136/gutjnl-2019-318930] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
614 Ierardi E, Losurdo G, Mileti A, Paolillo R, Giorgio F, Principi M, Di Leo A. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science.Antibiotics (Basel). 2020;9. [PMID: 32486473 DOI: 10.3390/antibiotics9060293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
615 Wu Y, Su T, Zhou X, Lu N, Li Z, Du Y. Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey. Helicobacter 2020;25:e12705. [PMID: 32476197 DOI: 10.1111/hel.12705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
616 Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Kinoshita K, Torii A, Yamada A, Suzuki H, Koike K. Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. JGH Open. 2020;4:909-914. [PMID: 33102763 DOI: 10.1002/jgh3.12360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
617 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
618 Tang X, Shen Y, Hu R, Yang T, Benghezal M, Li H, Tang H. Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori. Helicobacter 2020;25:e12703. [PMID: 32453910 DOI: 10.1111/hel.12703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
619 Butorova LI, Ardatskaya MD, Osadchuk MA, Kadnikova NG, Lukianova EI, Plavnik RG, Sayutina EV, Topchiy TB, Tuayeva EM. [Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection]. Ter Arkh 2020;92:64-9. [PMID: 32598700 DOI: 10.26442/00403660.2020.04.000647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
620 Jehanne Q, Bénéjat L, Mégraud F, Bessède E, Lehours P. Evaluation of the Allplex™ H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies. Helicobacter 2020;25:e12702. [PMID: 32426894 DOI: 10.1111/hel.12702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
621 Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility‐guided therapy for Helicobacter pylori ‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies. Helicobacter 2020;25. [DOI: 10.1111/hel.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
622 Melenotte C, Mezouar S, Mège JL, Gorvel JP, Kroemer G, Raoult D. Bacterial infection and non-Hodgkin's lymphoma. Crit Rev Microbiol 2020;46:270-87. [PMID: 32412856 DOI: 10.1080/1040841X.2020.1760786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
623 Jonaitis P, Jonaitis L, Kupcinskas J. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. Curr Drug Metab. 2020;. [PMID: 32407266 DOI: 10.2174/1389200221666200514081442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
624 Gottesmann M, Goycoolea FM, Steinbacher T, Menogni T, Hensel A. Smart drug delivery against Helicobacter pylori: pectin-coated, mucoadhesive liposomes with antiadhesive activity and antibiotic cargo. Appl Microbiol Biotechnol 2020;104:5943-57. [PMID: 32399588 DOI: 10.1007/s00253-020-10647-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
625 Zhu Q, Wu X, Tang M, Wu L. Observation of tumor-associated macrophages expression in gastric cancer and its clinical pathological relationship. Medicine (Baltimore) 2020;99:e19839. [PMID: 32332633 DOI: 10.1097/MD.0000000000019839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
626 Yulizal OK, Lelo A, Ilyas S, Kusumawati RL. The effect of snakehead fish extract supplementation to first-line eradication regimen on macrophage migration inhibitory factor (MIF) expression in rats induced by Helicobacter pylori infection. J Adv Vet Anim Res 2020;7:209-17. [PMID: 32607351 DOI: 10.5455/javar.2020.g411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
627 Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 2020;11:1314-23. [PMID: 32362221 DOI: 10.1080/19490976.2020.1754118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
628 Choi Y, Kim N, Yun CY, Choi YJ, Yoon H, Shin CM, Park YS, Ahn SH, Joong Park D, Lee HS, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH, Lee DH, Kim HH. Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years. Gastric Cancer 2020;23:1051-63. [PMID: 32361784 DOI: 10.1007/s10120-020-01076-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
629 Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection. Am J Gastroenterol 2020;115:716-22. [PMID: 32356953 DOI: 10.14309/ajg.0000000000000626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
630 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
631 Aumpan N, Vilaichone RK, Gamnarai P, Sanglutong L, Ratanachu-Ek T, Mahachai V, Yamaoka Y. Prevalence and Antibiotic Resistance Patterns of Helicobacter pylori Infection in Koh Kong, Cambodia. Asian Pac J Cancer Prev 2020;21:1409-13. [PMID: 32458649 DOI: 10.31557/APJCP.2020.21.5.1409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
632 Papaefthymiou A, Doulberis M, Polyzos SA, Kountouras J. National consensus on Helicobacter pylori infection: the next-day challenge. Ann Gastroenterol 2020;33:324-5. [PMID: 32382241 DOI: 10.20524/aog.2020.0469] [Reference Citation Analysis]
633 Zhang Y, Zhu Y, Zhao Z, Zhao J, Wang T, Yang J, Chen D, Lan C. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. European Journal of Gastroenterology & Hepatology 2020;32:563-8. [DOI: 10.1097/meg.0000000000001646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
634 Li RJ, Dai YY, Qin C, Li XH, Qin YC, Pan Y, Huang YY, Huang ZS, Huang YQ. Treatment strategies and preventive methods for drug-resistant Helicobacter pylori infection. World J Meta-Anal 2020; 8(2): 98-108 [DOI: 10.13105/wjma.v8.i2.98] [Reference Citation Analysis]
635 Akbulut S, Caliskan AR, Saritas H, Demyati K, Bilgic Y, Unsal S, Koc C, Yilmaz S. Analysis of risk factors affecting the development of peptic ulcer perforation: case-control study. Prz Gastroenterol 2021;16:23-8. [PMID: 33986884 DOI: 10.5114/pg.2020.94744] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
636 Shin SP, Bang CS, Lee JJ, Baik GH. Helicobacter pylori Infection in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Gut Liver 2019;13:628-41. [PMID: 30970438 DOI: 10.5009/gnl18517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
637 Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744 [PMID: 32351290 DOI: 10.3748/wjg.v26.i15.1733] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
638 Di J, Zhang J, Cao L, Huang TT, Zhang JX, Mi YN, Xiao X, Yan PP, Wu ML, Yao T, Liu DZ, Liu J, Cao YX. Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2020;64:e02192-19. [PMID: 32071054 DOI: 10.1128/AAC.02192-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
639 Sugimoto M, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis. World J Gastroenterol 2020; 26(15): 1820-1840 [PMID: 32351296 DOI: 10.3748/wjg.v26.i15.1820] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
640 Gao C, Zhang D, Zhang T, Wang J, Han S, Graham DY, Lu H. PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis. Helicobacter 2020;25. [DOI: 10.1111/hel.12692] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
641 Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM. Non‐bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real‐life study. Helicobacter 2020;25. [DOI: 10.1111/hel.12694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
642 Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, Almadi M. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8. [PMID: 32295933 DOI: 10.4103/sjg.SJG_626_19] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
643 Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. Helicobacter 2020;25:e12693. [PMID: 32285569 DOI: 10.1111/hel.12693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
644 Alsulaimany FAS, Awan ZA, Almohamady AM, Koumu MI, Yaghmoor BE, Elhady SS, Elfaky MA. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina (Kaunas) 2020;56:E169. [PMID: 32283700 DOI: 10.3390/medicina56040169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
645 Ivashkin VT, Maev IV, Tsar’kov PV, Korolev MP, Andreev DN, Baranskaya EK, Burkov SG, Derinov AA, Efetov SK, Lapina TL, Pavlov PV, Pirogov SS, Tkachev AV, Trukhmanov AS, Fedorov ED, Sheptulin AA. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:49-70. [DOI: 10.22416/1382-4376-2020-30-1-49-70] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
646 Zhou G. Helicobacter pylori Recurrence after Eradication Therapy in Jiangjin District, Chongqing, China. Gastroenterol Res Pract 2020;2020:7510872. [PMID: 32328098 DOI: 10.1155/2020/7510872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
647 Doulberis M, Srivastava S, Polyzos SA, Kountouras J, Papaefthymiou A, Klukowska-Rötzler J, Blank A, Exadaktylos AK, Srivastava DS. Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. J Clin Med 2020;9:E933. [PMID: 32235601 DOI: 10.3390/jcm9040933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
648 Park CH, Yang DH, Kim JW, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer.Clin Endosc. 2020;53:142-166. [PMID: 32252507 DOI: 10.5946/ce.2020.032] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 17.5] [Reference Citation Analysis]
649 Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol 2020;35:1495-502. [PMID: 32181516 DOI: 10.1111/jgh.15037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
650 Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux PA, Vasseur P, Thiebault Q, Lefèvre C, de Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C. Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay. J Clin Microbiol 2020;58:e01787-19. [PMID: 31996442 DOI: 10.1128/JCM.01787-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
651 Ji Y, Liang X, Lu H. Analysis of by high-throughput sequencing: Helicobacter pylori infection and salivary microbiome. BMC Oral Health 2020;20:84. [PMID: 32197614 DOI: 10.1186/s12903-020-01070-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
652 Uddin R, Khalil W. A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori. Genes Genomics 2020;42:519-41. [PMID: 32193857 DOI: 10.1007/s13258-020-00921-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
653 Liatsos C, Papaefthymiou A, Kyriakos N, Giakoumis M, Kountouras J, Galanopoulos M, Apostolopoulos P, Georgopoulos SD, Mavrogiannis C, Exadaktylos AK, Srivastava DS, Rokkas T, Doulberis M. Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? Medicina (Kaunas) 2020;56:E133. [PMID: 32197498 DOI: 10.3390/medicina56030133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
654 Wang R, Bai D, Xiang W, Zhang YF, Ba KY, Chen XZ; SIGES research group. Helicobacter pylori prevalence in the Southwest of China: A protocol for systematic review. Medicine (Baltimore) 2020;99:e19369. [PMID: 32176059 DOI: 10.1097/MD.0000000000019369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
656 Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter 2020;25:e12686. [PMID: 32173974 DOI: 10.1111/hel.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
657 Ding SZ. Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer. World J Gastroenterol 2020; 26(10): 995-1004 [PMID: 32205991 DOI: 10.3748/wjg.v26.i10.995] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
658 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira D. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics (Basel) 2020;9:E121. [PMID: 32183165 DOI: 10.3390/antibiotics9030121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
659 Domșa AT, Lupușoru R, Gheban D, Șerban R, Borzan CM. Helicobacter pylori Gastritis in Children-The Link between Endoscopy and Histology. J Clin Med 2020;9:E784. [PMID: 32183130 DOI: 10.3390/jcm9030784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
660 Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, Huo L, Du Q, Xu J, Chen Y, Zhang X, Zhang G, Yang G, Zuo X, Guo T, Lu Y, Wang F, Wang X, Zhuang K, Chen S, Liu W, Lu N; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect 2020;9:548-57. [PMID: 32160805 DOI: 10.1080/22221751.2020.1737579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
661 Lim SH, Kim N, Kim SE, Baik GH, Lee JY, Park KS, Shin JE, Song HJ, Myung D, Choi SC, Kim HJ. A Comparison of Accuracy between IMMULITE2000® and GENEDIA® for Helicobacter pylori Infection. Korean J Helicobacter Up Gastrointest Res 2020;20:54-62. [DOI: 10.7704/kjhugr.2019.0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
662 Salillas S, Sancho J. Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens. Int J Mol Sci 2020;21:E1881. [PMID: 32164177 DOI: 10.3390/ijms21051881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
663 Krzyżek P, Grande R. Transformation of Helicobacter pylori into Coccoid Forms as a Challenge for Research Determining Activity of Antimicrobial Substances. Pathogens 2020;9:E184. [PMID: 32143312 DOI: 10.3390/pathogens9030184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
664 Kumar S, Metz DC, Ginsberg GG, Kaplan DE, Goldberg DS. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther 2020;51:781-8. [PMID: 32133681 DOI: 10.1111/apt.15677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
665 Özer Etik D, Sezer S, Suna N, Öztaş E, Kılıç ZMY. Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication? Turk J Gastroenterol 2019;30:667-72. [PMID: 31258136 DOI: 10.5152/tjg.2019.18793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
666 Xie S, Wang S, Xue L, Middleton DRS, Guan C, Hao C, Wang J, Li B, Chen R, Li X, Wei W. Helicobacter pylori Is Associated With Precancerous and Cancerous Lesions of the Gastric Cardia Mucosa: Results of a Large Population-Based Study in China. Front Oncol 2020;10:205. [PMID: 32195175 DOI: 10.3389/fonc.2020.00205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
667 Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. Drug Saf 2019;42:993-1003. [PMID: 31069703 DOI: 10.1007/s40264-019-00821-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
668 Zhao Y, Zhang J, Cheng ASL, Yu J, To KF, Kang W. Gastric cancer: genome damaged by bugs. Oncogene 2020;39:3427-42. [PMID: 32123313 DOI: 10.1038/s41388-020-1241-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
669 Liu M, Zhong Y, Chen J, Liu Y, Tang C, Wang X, Zhang Y, Wang P, Logan SM, Chen W, Wei B. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine 2020;38:3031-41. [PMID: 32139315 DOI: 10.1016/j.vaccine.2020.02.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
670 Lin T, Wu D, Tsay F, Tsai K, Tsai T, Peng N, Kao S, Chen W, Chen Y, Hsu P. Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection. Journal of the Chinese Medical Association 2020;83:233-7. [DOI: 10.1097/jcma.0000000000000256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
671 Guo CG, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut 2020;69:445-52. [PMID: 31101690 DOI: 10.1136/gutjnl-2019-318352] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
672 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019;114:900-6. [PMID: 31095531 DOI: 10.14309/ajg.0000000000000223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
673 Bordin DS, Voynovan IN, Embutnieks YV, Nyssen OP, Megraud F, O`morain C, Perez-gisbert J. European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii arkhiv 2020;92:12-8. [DOI: 10.26442/00403660.2020.02.000567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
674 Jekarl DW, Choi H, Kim JY, Lee S, Gweon TG, Lee HK, Kim Y. Evaluating Diagnostic Tests for Helicobacter pylori Infection Without a Reference Standard: Use of Latent Class Analysis. Ann Lab Med 2020;40:68-71. [PMID: 31432642 DOI: 10.3343/alm.2020.40.1.68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
675 Arismendi Sosa AC, Salinas Ibáñez AG, Pérez Chaca MV, Penissi AB, Gómez NN, Vega AE. Inflammatory response induced by Helicobacter pylori infection in lung. Microb Pathog 2020;142:104103. [PMID: 32112810 DOI: 10.1016/j.micpath.2020.104103] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
676 Saranathan R, Levi MH, Wattam AR, Malek A, Asare E, Behin DS, Pan DH, Jacobs WR Jr, Szymczak WA. Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing. J Clin Microbiol 2020;58:e01591-19. [PMID: 31801839 DOI: 10.1128/JCM.01591-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
677 Spinzi G, Milano A, Brosolo P, Da Massa Carrara P, Labardi M, Merighi A, Riccardi L, Torresan F. The Italian Society for Digestive Endoscopy (SIED) accreditation and quality improving project based on international standards. Endosc Int Open 2020;8:E338-45. [PMID: 32140556 DOI: 10.1055/a-1096-0219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
678 Hamidi S, Badmasti F, Sadeghpour Heravi F, Safapoor MH, Mohammad Ali Tabrizi A, Ghorbani M, Azizi O. Antibiotic resistance and clonal relatedness of Helicobacter pylori strains isolated from stomach biopsy specimens in northeast of Iran. Helicobacter 2020;25:e12684. [PMID: 32074664 DOI: 10.1111/hel.12684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
679 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
680 Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
681 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
682 Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
683 Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol 2020;35:1107-16. [PMID: 31984532 DOI: 10.1111/jgh.14992] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
684 Šeligová B, Lukáč Ľ, Bábelová M, Vávrová S, Sulo P. Diagnostic reliability of nested PCR depends on the primer design and threshold abundance of Helicobacter pylori in biopsy, stool, and saliva samples. Helicobacter 2020;25:e12680. [PMID: 32057175 DOI: 10.1111/hel.12680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
685 Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
686 Périco LL, Emílio-Silva MT, Ohara R, Rodrigues VP, Bueno G, Barbosa-Filho JM, Rocha LRMD, Batista LM, Hiruma-Lima CA. Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. Biomolecules 2020;10:E265. [PMID: 32050614 DOI: 10.3390/biom10020265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
687 Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine (Lond) 2020;15:527-42. [PMID: 32028847 DOI: 10.2217/nnm-2019-0329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
688 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
689 Toyoshima O, Nishizawa T, Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J Gastroenterol 2020; 26(5): 466-477 [PMID: 32089624 DOI: 10.3748/wjg.v26.i5.466] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 17.5] [Reference Citation Analysis]
690 Sugimoto M, Murata M, Kawai T. How long should patients be surveyed for gastric cancer risk after Helicobacter pylori eradication therapy? 10 years is no longer enough. J Gastroenterol 2020;55:577-8. [DOI: 10.1007/s00535-020-01674-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
691 Yin G, Bie S, Gu H, Shu X, Zheng W, Peng K, Zhao H, Li F, Chen B, Botchway BOA, Fang M, Jiang M. Application of gene chip technology in the diagnostic and drug resistance detection of Helicobacter pylori in children. J Gastroenterol Hepatol 2020;35:1331-9. [PMID: 31930581 DOI: 10.1111/jgh.14980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
692 Khare A, Gaur S. Cholesterol-Lowering Effects of Lactobacillus Species. Curr Microbiol 2020;77:638-44. [DOI: 10.1007/s00284-020-01903-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
693 Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci 2020;65:3639-46. [DOI: 10.1007/s10620-020-06115-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
694 Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil 2020;26:29-50. [PMID: 31917913 DOI: 10.5056/jnm19209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 12.5] [Reference Citation Analysis]
695 Korona-Glowniak I, Glowniak-Lipa A, Ludwiczuk A, Baj T, Malm A. The In Vitro Activity of Essential Oils against Helicobacter Pylori Growth and Urease Activity. Molecules 2020;25:E586. [PMID: 32013183 DOI: 10.3390/molecules25030586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
696 Miqueleiz-Zapatero A, Alba-Rubio C, Domingo-García D, Cantón R, Gómez-García de la Pedrosa E, Aznar-Cano E, Leiva J, Montes M, Sánchez-Romero I, Rodríguez-Díaz JC, Alarcón-Cavero T; Grupo de Trabajo de Diagnóstico Microbiológico de Helicobacter pylori., Integrantes del Grupo de Trabajo de Diagnóstico Microbiológico de Helicobacter pylori Andalucía., Aragón., Principado de Asturias., Islas Baleares., Canarias., Cantabria., Castilla y León., Castilla-La Mancha., Cataluña., Comunidad Valenciana., Extremadura., Galicia., Comunidad de Madrid., Comunidad Foral de Navarra., País Vasco., La Rioja. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38:410-6. [PMID: 31987710 DOI: 10.1016/j.eimc.2019.11.008] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
697 Milivojevic V, Milosavljevic T. Burden of Gastroduodenal Diseases from the Global Perspective. Curr Treat Options Gastroenterol 2020. [PMID: 31993967 DOI: 10.1007/s11938-020-00277-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
698 Annibale B, Esposito G, Lahner E. A current clinical overview of atrophic gastritis. Expert Review of Gastroenterology & Hepatology 2020;14:93-102. [DOI: 10.1080/17474124.2020.1718491] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
699 Du Y, Zhu H, Liu J, Li J, Chang X, Zhou L, Chen M, Lu N, Li Z. Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai). J Gastroenterol Hepatol. 2020;35:624-629. [PMID: 31788864 DOI: 10.1111/jgh.14947] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
700 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
701 Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE. Arq Gastroenterol 2019;56:361-6. [PMID: 31721972 DOI: 10.1590/S0004-2803.201900000-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
702 Buti L, Ruiz-Puig C, Sangberg D, Leissing TM, Brewer RC, Owen RP, Sgromo B, Royer C, Ebner D, Lu X. CagA-ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids. Proc Natl Acad Sci U S A 2020;117:2645-55. [PMID: 31964836 DOI: 10.1073/pnas.1908787117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
703 Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 2020;25:e12679. [PMID: 31958193 DOI: 10.1111/hel.12679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
704 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
705 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
706 Valenzano M, Bisio A, Grassi G. Helicobacter pylori and diabetes mellitus: a controversial relationship. Minerva Endocrinol 2019;44:301-9. [PMID: 31304727 DOI: 10.23736/S0391-1977.19.03021-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
707 Rodríguez Gómez ER, Otero Regino W, Monterrey PA, Trespalacios Rangel AA. cagA gene EPIYA motif genetic characterization from Colombian Helicobacter pylori isolates: Standardization of a molecular test for rapid clinical laboratory detection. PLoS One 2020;15:e0227275. [PMID: 31923209 DOI: 10.1371/journal.pone.0227275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
708 Miftahussurur M, Fauzia KA, Nusi IA, Setiawan PB, Syam AF, Waskito LA, Doohan D, Ratnasari N, Khomsan A, Adnyana IK, Akada J, Yamaoka Y. E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study. BMC Res Notes 2020;13:22. [PMID: 31924273 DOI: 10.1186/s13104-019-4877-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
709 Dinis-Ribeiro M, Kuipers EJ. How to Manage a Patient With Gastric Intestinal Metaplasia: An International Perspective. Gastroenterology 2020;158:1534-7. [PMID: 31926996 DOI: 10.1053/j.gastro.2020.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
710 Peng C, Hu Y, Ge ZM, Zou QM, Lyu NH. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med 2019;5:243-51. [PMID: 32055783 DOI: 10.1016/j.cdtm.2019.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
711 Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Chiu MC, Kuo CC, Weng YJ, Bair MJ, Wu MS, Luo JC, Liou JM. Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. J Formos Med Assoc 2020;119:1626-33. [PMID: 31926791 DOI: 10.1016/j.jfma.2019.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
712 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
713 Gao C, Du SY, Fang L, Fan YH, Song AP, Chen H. Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance. Infect Drug Resist 2020;13:69-79. [PMID: 32021321 DOI: 10.2147/IDR.S232169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
714 Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med 2020;14:43-50. [PMID: 31907860 DOI: 10.1007/s11684-019-0706-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
715 Barinova AS, Naletov AV, Naletov SV, Masyuta DI, Perederiy EA. Influence of parental compliance on the effectiveness of treatment of chronic gastroduodenal pathology in children. RRP 2019;5:69-74. [DOI: 10.3897/rrpharmacology.5.48560] [Reference Citation Analysis]
716 O'Connor A, Liou JM, Gisbert JP, O'Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter 2019;24 Suppl 1:e12640. [PMID: 31486235 DOI: 10.1111/hel.12640] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
717 Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019;24 Suppl 1:e12635. [PMID: 31486242 DOI: 10.1111/hel.12635] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
718 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
719 Seo SI, Do BJ, Kang JG, Kim HS, Jang MK, Kim HY, Shin WG. Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance. J Clin Med 2019;9:E54. [PMID: 31881688 DOI: 10.3390/jcm9010054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
720 Kumar S, Sangitha R, Nachamkin I, Metz DC. Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley. GastroHep 2020;2:6-12. [PMID: 32377173 DOI: 10.1002/ygh2.382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
721 Yang J, Zhang Y, Fan L, Zhu YJ, Wang TY, Wang XW, Chen DF, Lan CH. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437-445. [PMID: 30807294 DOI: 10.14309/ajg.0000000000000132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
722 Rezaei S, Talebi Bezmin Abadi A, Mohabatti Mobarez A. Metronidazole-resistant Helicobacter pylori isolates without rdxA mutations obtained from Iranian dyspeptic patients. New Microbes New Infect 2020;34:100636. [PMID: 31993205 DOI: 10.1016/j.nmni.2019.100636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
723 Smith SM, O'Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 2019;35:6-13. [PMID: 30489412 DOI: 10.1097/MOG.0000000000000497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
724 Schulz C, Schütte K, Mayerle J, Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond.Therap Adv Gastroenterol. 2019;12:1756284819894062. [PMID: 31897087 DOI: 10.1177/1756284819894062] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
725 Zhang L, Lan Y, Wang Q, Zhang Y, Si X. Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori. Gastroenterol Res Pract 2019;2019:9251879. [PMID: 31933634 DOI: 10.1155/2019/9251879] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
726 Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial. World J Gastroenterol 2019; 25(46): 6743-6751 [PMID: 31857776 DOI: 10.3748/wjg.v25.i46.6743] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
727 Arieira C, Boal Carvalho P, Dias de Castro F, Cotter J. Esophagogastroduodenoscopy Findings in Patients on the Waiting List for Bariatric Surgery. GE Port J Gastroenterol 2019;26:389-95. [PMID: 31832493 DOI: 10.1159/000495770] [Reference Citation Analysis]
728 Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
729 Chang YW, Park YM, Oh CH, Oh SJ, Cho JH, Kim JW, Jang JY. Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy. Korean J Intern Med 2020;35:574-81. [PMID: 31830776 DOI: 10.3904/kjim.2019.139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
730 Ofori EG, Adinortey CA, Bockarie AS, Kyei F, Tagoe EA, Adinortey MB. Helicobacter pylori Infection, Virulence Genes' Distribution and Accompanying Clinical Outcomes: The West Africa Situation. Biomed Res Int 2019;2019:7312908. [PMID: 31886245 DOI: 10.1155/2019/7312908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
731 Kim Y, Chung WC. Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance. Korean J Helicobacter Up Gastrointest Res 2019;19:225-30. [DOI: 10.7704/kjhugr.2019.0019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
732 McNicholl AG, Garre A, Llorca L, Bujanda L, Molina-Infante J, Barenys M, Perez J, Guerrero-Torres MD, Tamayo E, Montes M, Prados-Manzano R, Sanchez-Garcia A, Ramas M, Valdez Blanco VB, Montoro M, Calvet X, Figuerola A, Lario S, Quilez E, Lanas A, Silva-Pomarino P, Perez-Aisa A, Donday MG, Belloc B, Montserrat-Torres A, Fernandez-Moreno N, Ramírez MJ, Alarcon T, Gisbert JP. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. Gastroenterol Hepatol 2020;43:117-25. [PMID: 31810793 DOI: 10.1016/j.gastrohep.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
733 Bartels LE, Pedersen AB, Kristensen NR, Vilstrup H, Stengaard-Pedersen K, Dahlerup JF. A positive Helicobacter pylori test is associated with low spondylarthritis incidence in a Danish historical cohort study. Rheumatol Int 2020;40:359-66. [PMID: 31802207 DOI: 10.1007/s00296-019-04487-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
734 Berthenet E, Bénéjat L, Ménard A, Varon C, Lacomme S, Gontier E, Raymond J, Boussaba O, Toulza O, Ducournau A, Buissonnière A, Giese A, Megraud F, Bessède E, Jehanne Q, Lehours P. Whole-Genome Sequencing and Bioinformatics as Pertinent Tools to Support Helicobacteracae Taxonomy, Based on Three Strains Suspected to Belong to Novel Helicobacter Species. Front Microbiol 2019;10:2820. [PMID: 31866982 DOI: 10.3389/fmicb.2019.02820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
735 Myint NPST, Zaw TT, Sain K, Waiyan S, Danta M, Cooper D, Aung NM, Kyi MM, Hanson J. Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability. J Gastroenterol Hepatol 2020;35:617-23. [PMID: 31758571 DOI: 10.1111/jgh.14942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
736 Puig I, Sanabria E, Feu F, Couto I, Blanco M, Alonso P, Gisbert JP, McNicholl AG, Seoane A, Bory F, Polo F, Orivé V, Ponce J, Borda F, Hervás A, Pérez-Aisa Á, Rivera R, Quintero E, Nicolás-Pérez D, Bujanda L, Rodrigo L, Calvet X; Spanish Gastroenterological Association Gastroduodenal Diseases Study Group. Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. Gastroenterol Hepatol 2020;43:79-86. [PMID: 31787375 DOI: 10.1016/j.gastrohep.2019.08.012] [Reference Citation Analysis]
737 Bair M, Chuang S, Lei W, Chen C, Tian H, Chiang T, Su WW, Lin C, Chung Lo Y, Jou Y, Wu C, Chia S, Wu M, Chen H, Chu C, Lee Y, Wang Y. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. Journal of Gastroenterology and Hepatology 2020;35:609-16. [DOI: 10.1111/jgh.14898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
738 Parreira P, Monteiro C, Graça V, Gomes J, Maia S, Gomes P, Gonçalves IC, Martins MCL. Surface Grafted MSI-78A Antimicrobial Peptide has High Potential for Gastric Infection Management. Sci Rep 2019;9:18212. [PMID: 31796755 DOI: 10.1038/s41598-019-53918-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
739 Serebrova SY, Kareva EN, Eremenko NN, Prokof’ev AB, Kurguzova DO, Drozdov VN, Lazareva NB, Komissarenko IA, Starodubtsev AK. Role of Drug – Drug Interactions in the Efficacy and Safety of Clarithromycin Treatment for Helicobacter Pylori Eradication. Pharm Chem J 2019;53:678-9. [DOI: 10.1007/s11094-019-02061-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
740 Miendje Deyi VY, Lare MS, Burette A, Ntounda R, Elkilic O, Cadranel S, Bontems P, Hallin M. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium. Diagnostic Microbiology and Infectious Disease 2019;95:114875. [DOI: 10.1016/j.diagmicrobio.2019.114875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
741 Mezmale L, Isajevs S, Bogdanova I, Polaka I, Krigere A, Rudzite D, Rudule A, Kikuste I, Parshutin S, Tazhedinov A, Mushinskiy D, Sametayev D, Belikhina T, Igissinov N, Park JY, Herrero R, Leja M. Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy. Asian Pac J Cancer Prev 2019;20:3825-9. [PMID: 31870128 DOI: 10.31557/APJCP.2019.20.12.3825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
742 Shakoor S, Platts-mills JA, Hasan R. Antibiotic-Resistant Enteric Infections. Infectious Disease Clinics of North America 2019;33:1105-23. [DOI: 10.1016/j.idc.2019.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
743 Liu DS, Wang YH, Zhu ZH, Zhang SH, Zhu X, Wan JH, Lu NH, Xie Y. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control 2019;8:192. [PMID: 31798838 DOI: 10.1186/s13756-019-0632-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
744 Mcnicholl AG, Gisbert JP. Reply. Clin Gastroenterol Hepatol 2019;17:2822-3. [PMID: 31757363 DOI: 10.1016/j.cgh.2019.05.054] [Reference Citation Analysis]
745 Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory Helicobacter pylori infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS 2020;128:25-34. [PMID: 31628820 DOI: 10.1111/apm.13001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
746 Li H, Marceau M, Yang T, Liao T, Tang X, Hu R, Xie Y, Tang H, Tay A, Shi Y, Shen Y, Yang T, Pi X, Lamichhane B, Luo Y, Debowski AW, Nilsson HO, Haslam SM, Mulloy B, Dell A, Stubbs KA, Marshall BJ, Benghezal M. East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide. PLoS Genet 2019;15:e1008497. [PMID: 31747390 DOI: 10.1371/journal.pgen.1008497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
747 Jarbøl DE, Lykkegaard J, Hansen JM, Munck A, Haastrup PF. Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice. Fam Pract 2019;36:758-64. [PMID: 31165863 DOI: 10.1093/fampra/cmz025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
748 Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, Suzuki H, Zali MR. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. J Clin Med. 2019;8. [PMID: 31744181 DOI: 10.3390/jcm8112004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
749 Schütte K, Malfertheiner P, Schulz C. What is the Relevance of Gastric Microbiota Beyond H. pylori? Curr Treat Options Gastroenterol 2019;17:619-27. [PMID: 31732849 DOI: 10.1007/s11938-019-00245-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
750 Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D. Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. Helicobacter 2020;25:e12668. [PMID: 31721371 DOI: 10.1111/hel.12668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
751 Walker MM, Talley NJ. Functional Dyspepsia in the Elderly. Curr Gastroenterol Rep 2019;21:54. [PMID: 31720909 DOI: 10.1007/s11894-019-0722-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
752 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Pathogens 2019;8:E228. [PMID: 31717683 DOI: 10.3390/pathogens8040228] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
753 Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, Rios E, Coppelli L, Barrientos L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens 2019;8:E226. [PMID: 31717523 DOI: 10.3390/pathogens8040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
754 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
755 Cho JH, Jeon SR, Jin SY, Park S. Analysis of factors associated with recovery of the serum pepsinogen ratio after Helicobacter pylori eradication: a long-term follow-up study in Korea. Scand J Gastroenterol 2019;54:1306-14. [PMID: 31702966 DOI: 10.1080/00365521.2019.1686058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
756 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
757 Yang L, Zhang J, Xu J, Wei X, Yang J, Liu Y, Li H, Zhao C, Wang Y, Zhang L, Gai Z. Helicobacter pylori Infection Aggravates Dysbiosis of Gut Microbiome in Children With Gastritis. Front Cell Infect Microbiol 2019;9:375. [PMID: 31781514 DOI: 10.3389/fcimb.2019.00375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
758 Papaefthymiou A, Liatsos C, Georgopoulos SD, Apostolopoulos P, Doulberis M, Kyriakos N, Giakoumis M, Papadomichelakis M, Galanopoulos M, Katsinelos P, Rokkas T, Kountouras J. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. Helicobacter 2020;25:e12666. [PMID: 31692137 DOI: 10.1111/hel.12666] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
759 Kishikawa H, Ojiro K, Nakamura K, Katayama T, Arahata K, Takarabe S, Miura S, Kanai T, Nishida J. Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication. Helicobacter. 2020;25:e12669. [PMID: 31680399 DOI: 10.1111/hel.12669] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
760 Khani S, Talebi Bezmin Abadi A, Mohabati Mobarez A. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients' Stomachs. Infect Drug Resist 2019;12:3415-20. [PMID: 31802920 DOI: 10.2147/IDR.S223602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [